Diabetes Connections | Type 1 Diabetes
The T1D news show you've been waiting for! Long-time broadcaster, blogger and diabetes mom Stacey Simms interviews prominent advocates, authors and speakers. Stacey asks hard questions of healthcare companies and tech developers and brings on "everyday' people living with type 1. Great for parents of T1D kids, adults with type 1 and anyone who loves a person with diabetes.
info_outline
When it’s even more than T1D: Stacy’s fight for health & hope
09/02/2025
When it’s even more than T1D: Stacy’s fight for health & hope
This week on Diabetes Connections.. when T1D is one of many chronic conditions. Stacy Abrams was diagnosed with type 1 at age five, and she’s faced a slew of other issues since then. Chronic fatigue, celiac, a long road to uncovering mold and environmental illness. She shares the highs and lows of that journey, what helped along the way, and why having a medical team that truly listens makes all the difference. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at Learn more about Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: info@diabetes-connections.
/episode/index/show/diabetesconnections/id/38050590
info_outline
In the News.. CRISPR transplant for type 1, T1D risk if dad has type 2, Metformin and the brain, oral GLP-1, and more!
08/29/2025
In the News.. CRISPR transplant for type 1, T1D risk if dad has type 2, Metformin and the brain, oral GLP-1, and more!
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: CRISPR modified cell transplant for type 1, risk of T1D if parent has a different type of diabetes, Metformin and the brain, oral GLP-1, and more! Find out more about Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX A 42-year-old man who has lived most of his life with type 1 diabetes has become the first human to receive a transplant of genetically modified insulin-producing cells. This marks the first pancreatic cell transplant in a human to sidestep the need for immunosuppressant drugs. “This is the most exciting moment of my scientific career,” says cell biologist Per-Ola Carlsson of Uppsala University in Sweden, who helped develop the procedure. The new treatment, he says, “opens the future possibility of treating not only diabetes but other autoimmune diseases.” This procedure uses the gene editing technique, CRISPR, to discourage the auto immune attack on the donor cells. Before the transplant, the participant had no measurable naturally produced insulin and was receiving daily doses of the hormone. But within four to 12 weeks following the transplant, his levels rose slightly on their own after meals—showing that the new beta cells were releasing some insulin in response to glucose. even though the new study is promising, it involved just one participant and is therefore preliminary. And longer-term monitoring is needed to confirm the therapy’s safety before it can be offered to more people. She also notes that the injected cells produced only 7 percent of the insulin needed for a person to be fully independent of additional medication. The researchers supplied the recipient with insulin doses to maintain healthy blood sugar levels. While Herold thinks it’s still too early to consider this approach for a cure, “these options are now here to change the disease in ways that have never been possible before,” he says. “There’s tremendous hope.” https://www.scientificamerican.com/article/type-1-diabetes-patients-insulin-production-restored-with-new-cell/ XX This one is interesting… a recent study shows that children of mothers with gestational diabetes or fathers with type 2 diabetes have higher chances of developing type 1 diabetes than kids whose parents do not have any type of diabetes. Specifically, the study found that children whose mothers had gestational diabetes during pregnancy were 94% more likely to develop type 1 diabetes compared to children of mothers without diabetes. Similarly, having a father with type 2 diabetes was linked to a 77% higher risk. The study also suggests a possible link between maternal type 2 diabetes and type 1 diabetes in children, although more data are needed to confirm whether the risk is real. "What is interesting is that type 1 diabetes is a disease of lack of the hormone insulin while gestational diabetes and type 2 diabetes stem mostly from the body's resistance to the hormone. What may be happening is that genes, environments and behaviors that create insulin resistance may also, in some cases, trigger the immune reactions that lead to type 1 diabetes," adds Dr. Dasgupta. A 2019 meta-analysis by researchers at Soochow University in China found that gestational diabetes was linked to a 66% higher risk of type 1 diabetes in children. This new study, which includes more than twice as many studies, offers a robust synthesis of current evidence and shows the risk is even greater than previously estimated. It is also the first meta-analysis to examine the link between paternal type 2 diabetes and type 1 diabetes in offspring. "Several mechanisms may be at play. Families often share lifestyle and eating habits, which can raise the likelihood that children will be affected. But beyond that, high blood sugar levels may also cause biological changes in parents that could increase their children's risk of developing type 1 diabetes," explains Laura Rendon, co-first author of the study, who completed an MSc in experimental medicine at The Institute and, as someone living with type 1 diabetes herself, finds deep personal meaning in conducting this research. For instance, the authors suggest that high blood sugar during pregnancy may stress the fetus's insulin-producing beta cells, reducing their number at birth or making them more vulnerable to damage later in life. It may also trigger epigenetic changes—modifications to proteins and molecules attached to DNA—that increase the risk. Likewise, high blood sugar in fathers with type 2 diabetes may cause epigenetic changes in their sperm, potentially influencing their child's risk of developing type 1 diabetes. XX Can a CGM help you lose weight? The company Signos is banking on it – the just got FDA approval for their system, which uses the over the counter Dexcom Stelo. The claim here is that the system will help track how food choices, activity, stress and sleep can all affect metabolism. Signos also works in partnership with the digital nutrition counseling startup Nourish. It currently offers a quarterly subscription plan, including six CGM sensors, for $139 per month. And they tell you don’t take any medical actions based on the app’s output without consulting a physician. https://www.fiercebiotech.com/medtech/fda-clears-signos-over-counter-cgm-powered-weight-loss-app XX Good news for T1D1, a free mobile app that helps people calculate insulin doses, track daily data, and share insights with healthcare providers. After being pulled off the market with similar apps a few years ago, it’s now back and FDA approved. Drew Mendelow created the app after his diagnosis at age 13. He came on the show last year and I’ll link his story up in the show notes. provided the initial funding to support the T1D1 efforts to redesign the app per FDA standards. , the registered manufacturer, enlisted a team of software engineers, regulatory experts, and design professionals to ensure T1D1 was FDA-ready. graciously conducted the Human Factors study to ensure safety and accuracy. T1D1 is now FDA-cleared as a Class II medical device and is the first over-the-counter insulin calculator cleared for individuals aged 2 and older. T1D1 is expected to be live in the AppStore and Google Play Store by October 2025. https://diabetes-connections.com/the-fda-took-down-this-teens-free-bolus-calculator-he-needs-your-help-to-bring-it-back/ XX Metformin has been the standard treatment for type 2 diabetes for more than six decades, yet scientists still do not fully understand how it works. A team from Baylor College of Medicine, working with international collaborators, has now identified an unexpected factor in its effectiveness: the brain. Their findings reveal a brain pathway involved in metformin’s glucose-lowering action, pointing to new strategies for treating diabetes with greater precision. The study was published in Science Advances. The researchers concentrated on a small protein called Rap1, located in a region of the brain known as the ventromedial hypothalamus (VMH). They discovered that metformin’s ability to lower blood sugar at clinically relevant doses depends on suppressing Rap1 activity in this brain area. “This discovery changes how we think about metformin,” Fukuda said. “It’s not just working in the liver or the gut, it’s also acting in the brain. We found that while the liver and intestines need high concentrations of the drug to respond, the brain reacts to much lower levels.” https://scitechdaily.com/after-60-years-scientists-uncover-hidden-brain-pathway-behind-diabetes-drug-metformin/ XX Looks like GLP-1 pills are moving ahead. Lilly says it’s version helped overweight adults with type 2 lose 10% of their body weights and lower A1C. Just two weeks ago, we were talking about how the same drug in people without diabetes had less than the stellar expected results. Orforglipron is a small-molecule pill that is easier to manufacture and package than wildly popular injectable drugs for obesity, such as Lilly's Zepbound and Novo Nordisk's NOVOb.CO rival treatment Wegovy, which are peptide mimics of the appetite-controlling GLP-1 hormone. In the 72-week study of more than 1,600 overweight or obese adults with type 2 diabetes, those who received the 36-milligram highest dose of orforglipron on average shed 10.5% of their weight, or about 23 pounds (10.43 kg), versus 2.2% for those who received a placebo, achieving the main goal of the trial. Patients on the lowest 6 mg dose of the Lilly drug lost 5.5% of their weight. XX An intervention that combined a low-calorie Mediterranean diet and exercise led to less diabetes incidence in older adults. Men had a greater diabetes risk reduction with the intervention than women. The study was based in Spain, and the diet may not be as easy to adhere to in the U.S. Among nearly 5,000 adults with metabolic syndrome and overweight or obesity in the PREDIMED-Plus trial, those who followed this intervention had a 31% lower risk for type 2 diabetes over 6 years relative to those who received only ad libitum Mediterranean diet advice (aHR 0.69, 95% CI 0.59-0.82). the Mediterranean diet focuses on high intake of plant-based foods, moderate consumption of fish, poultry, and dairy with optional red wine, and low intake of red meats, sweets, and sugar-sweetened beverages. Common foods featured in the diet include extra-virgin olive oil, fruits, vegetables, legumes, nuts, and whole grains. However, Sharon Herring, MD, MPH, and Gina Tripicchio, PhD, MSEd, both of Temple University in Philadelphia, pointed out that this study was conducted solely in Spain, and sticking to this type of diet may be more challenging in countries like the U.S. "Participants in the study received extra-virgin olive oil to support adherence and retention; in the United States, prices of extra-virgin olive oil have nearly doubled since 2021 due to a combination of factors including climate change, rising production costs, supply chain disruptions, and now tariffs," they noted in an accompanying editorial. "[T]he large number of dietitian contacts during the study may prove difficult to scale broadly in the United States given challenges with health care access and reimbursement for prevention services." XX A group of Canadian researchers has identified an unexpected way to lower blood sugar and protect the liver: by capturing a little-known fuel produced by gut bacteria before it enters the body and causes harm. The findings, published in Cell Metabolism, could open the door to new therapies to treat metabolic diseases like type 2 diabetes and fatty liver disease. Scientists from McMaster University, Université Laval, and the University of Ottawa discovered that a molecule generated by gut microbes can cross into the bloodstream, where it drives the liver to overproduce glucose and fat. By designing a method to trap this molecule in the gut before it reaches circulation, they achieved striking improvements in blood sugar regulation and fatty liver disease in obese mice. https://scitechdaily.com/scientists-discover-a-surprising-new-way-to-fight-diabetes/ XX Dexcom, which specializes in technology for glucose biosensing, will lay off 350 workers, with nearly 200 of them in San Diego, according to the San Diego Union Tribune. The bulk of the local jobs being lost are focused on Dexcom operations and manufacturing. The Dexcom development follows cutbacks to Verily, a life sciences company that is a subsidiary of Alphabet, Google’s corporate parent. Verily’s work included a project with Dexcom on wearable glucose sensors. CEO Stephen Gillett, in a memo obtained by the publication, said there will be “workforce reductions across Verily.” A representative for Verily confirmed to Business Insider that “we have made the difficult decision to discontinue manufacturing medical devices and will no longer be supporting them going forward.” XX Front office changes at Insulet. Eric Benjamin, former chief product and customer experience officer, will take the role of chief operating officer, effective immediately. Manoj Raghunandanan Mu-NOHJ Rug-a-nun-da-nun to the position of chief growth officer, leading Insulet’s new growth organization. The appointments are some of CEO Ashley McEvoy’s first changes since she was hired in April. The appointments come after McEvoy outlined four priorities for Insulet on an August earnings call: enhancing the company’s commercial capabilities, building Insulet’s brand and direct-to-consumer capabilities, driving growth outside of the U.S. and accelerating the pace of innovation. XX XX Want to highlight The Children's Diabetes Foundation in Colorado – they held a medal ceremony for patients of the Barbara Davis Center who've lived with Type 1 diabetes for 50 years or more. There were 87 medal recipients in the ceremony including Dana Davis, Executive Director of the Children's Diabetes Foundation and the daughter of the founders of the Barbara Davis Center. Davis shared: "When you got Type1 diabetes in the 70s, they thought you shouldn't have children. They thought you weren't going to live past 30 or 40. It was definitely very different," Davis said. https://www.cbsnews.com/colorado/news/barbara-davis-center-celebrates-colorado-type-1-diabetes-patients-milestone/
/episode/index/show/diabetesconnections/id/38020855
info_outline
Why this endo is pushing for a diabetes drug you've probably never heard of (and the FDA has rejected).
08/26/2025
Why this endo is pushing for a diabetes drug you've probably never heard of (and the FDA has rejected).
We've got an important update on a diabetes drug you may have never heard about. Sotagliflozin is known to have big benefits for people with type 2 but getting it approved for type 1 has been frustrating to say the least. The FDA has twice declined to approve it for people with T1D, but experts – including my guest – are pushing and hoping that will soon change. I’m talking to Dr. Steve Edleman, an endocrinologist who lives with type 1 and heads up the group We’ll talk about the risks that come with sotogliflozin, how continuous ketone monitoring could change the game, and what you can do to push for change. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at Learn more about Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: info@diabetes-connections.
/episode/index/show/diabetesconnections/id/37948810
info_outline
Ask Me Anything: Unfiltered Wisdom from Natalie Bellini and Julia Blanchette, two healthcare providers who live with type 1 diabetes
08/19/2025
Ask Me Anything: Unfiltered Wisdom from Natalie Bellini and Julia Blanchette, two healthcare providers who live with type 1 diabetes
We've got a funny, informative, helpful and no holds barred “Ask Me Anything” panels. Recorded at Moms’ Night Out in Cleveland, you’ll hear from two incredible experts who’ve lived with type 1 diabetes for decades—Julia Blanchette, PhD, RN, CDCES, and Natalie Bellini, DNP, FNP-BC, CDCES. We tackle everything from helping grandparents understand modern T1D care, to balancing diabetes in a marriage, to managing ADHD alongside diabetes in teens. We’ll also dig into why screening for type 1 is so important—and how to find the community and resources that make life with diabetes just a little bit easier. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us for a Join us at Learn more about Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: info@diabetes-connections.
/episode/index/show/diabetesconnections/id/37854150
info_outline
In the News... GLP-1 oral pill moves forward, Medtronic-Abbott sensor unveiled, Afrezza submitted for kids, diabetes scholarships and more!
08/15/2025
In the News... GLP-1 oral pill moves forward, Medtronic-Abbott sensor unveiled, Afrezza submitted for kids, diabetes scholarships and more!
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: cancer reserach may lead to T1D treatment, GLP-1 oral pill moves forward, Tandem pharmacy moves, Medtronic-Abbott sensor unveield, parents of kids with T1D see income drop, Mannkind submits Afrezza for pediatrics, diabetes scholarships and more! Find out more about Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Cornell researchers have developed an implant system that can treat type 1 diabetes by supplying extra oxygen to densely packed insulin-secreting cells, without the need for immunosuppression. The system could also potentially provide long-term treatment for a range of chronic diseases. This lab has produced previous implantable devices that have proved effective in controlling blood sugar in diabetic mice, but they can only last so long. "It's the proof of concept. We really proved that oxygenation is important, and oxygenation will support high cell-density capsules," Tempelman said. "The capsules are immune protective and last for a long time without having some kind of fouling of the membrane. The body never likes it when you put a foreign substance in. So that's the engineering in the Ma Lab, to look for materials and coatings for the materials that are immune protective, but also don't invoke excess response from the body because of the material." The next step will be to implant the system in a pig model, and also test it with human stem cells. The researchers are interested in eventually trying to use the system for implanting different cell types in humans for long-term treatment of chronic diseases, according to Tempelman, who is CEO of Persista Bio Inc., a new startup she founded with Ma and Flanders that is licensing these technologies. XX Mayo Clinic cancer research may be big news for T1D. After identifying a sugar molecule that cancer cells use on their surfaces to hide from the immune system, the researchers have found the same molecule may eventually help in the treatment of type 1. Cancer cells use a variety of methods to evade immune response, including coating themselves in a sugar molecule known as sialic acid. The researchers found in a preclinical model of type 1 diabetes that it's possible to dress up beta cells with the same sugar molecule, enabling the immune system to tolerate the cells. The findings show that it's possible to engineer beta cells that do not prompt an immune response In the preclinical models, the team found that the engineered cells were 90% effective in preventing the development of type 1 diabetes. The beta cells that are typically destroyed by the immune system in type 1 diabetes were preserved. XX A daily pill may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic, according to results of a clinical trial announced by Eli Lilly on Thursday morning. The drug, orforglipron, is a GLP-1, a class of drugs that have become blockbusters because of their weight-loss effects. But the GLP-1s on the market now are expensive, must be kept refrigerated and must be injected. A pill that produces similar results has the potential to become far more widely used, though it is also expected to be expensive. Lilly said it would seek approval from the Food and Drug Administration later this year to market orforglipron for obesity and early in 2026 for diabetes. https://www.nytimes.com/2025/04/17/health/pill-glp-1-eli-lilly.html XX Use of diabetes technology has dramatically increased and glycemic control has improved among people with type 1 diabetes (T1D) in the US over the past 15 years, but at the same time, overall achievement of an A1c level < 7% remains low and socioeconomic and racial disparities have widened. These findings came from an analysis of national electronic health records of nearly 200,000 children and adults with T1D by Michael Fang, PhD, of the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues. The study was published online on August 11, 2025, in JAMA Network Open. Use of continuous glucose monitors (CGMs) increased substantially from 2009-2011 to 2021-2023, from less than 5% in both children and adults to more than 80% and over half, respectively. While A1c levels did drop over the 15 years, just 1 in 5 children and slightly over a quarter of adults achieved a level < 7%. The average A1c level stayed above 8%, with ethnic minorities and low-income patients seeing the smallest gains. XX Inflammation may predict how well people with diabetes respond to depression treatment, and the effects differ dramatically between type 1 and type 2 diabetes. Diabetes and depression often appear together. Indeed, depression is more than three times more prevalent in people with type 1 diabetes (T1D) and nearly twice as prevalent in people with type 2 diabetes (T2D). When they appear together, treatment for depression can vary widely. In a new study, researchers from the German Diabetes Center (DDZ), the Research Institute of the Diabetes Academy Mergentheim (FIDAM), and the German Center for Diabetes Research (DZD) investigated how inflammation in the body relates to improvement in depression symptoms in people with T1D and T2D. The researchers combined data from three previous German randomized clinical trials that aimed to reduce elevated depressive symptoms and diabetes distress in people with type 1 or type 2 diabetes. Diabetes distress is characterized by feelings of overwhelm, frustration, guilt and worry about diabetes management and its potential complications. A total of 332 participants with T1D and 189 with T2D who had completed both a baseline and 12-month follow-up examination were included in the present study. Measures included depression using the Center for Epidemiological Studies Depression scale (CES-D), blood tests for 76 inflammatory biomarkers, and symptoms broken down into cognitive-affective (e.g., feeling hopeless), somatic (e.g., poor sleep, fatigue), and anhedonia (loss of pleasure) clusters. After adjusting for factors like age, body mass index (BMI), diabetes duration, cholesterol, and co-existing illnesses, the researchers found that in patients with T1D, higher baseline inflammation was linked to smaller improvements in depression. Inflammation seemed to be more connected to physical/somatic symptoms in T1D patients. In those with T2D, higher baseline inflammation was linked to greater improvements in depression. For these patients, the effect was strongest for cognitive-affective and anhedonia – so, emotional and motivational – symptoms. The researchers weren’t sure what caused the difference between T1D and T2D, but they suggest it might be due to the different forms of immune activation seen in each condition. That is, autoimmune processes in type 1 and metabolic inflammation in type 2. XX Parents of children diagnosed with type 1 diabetes suffer an income drop in the years following the diagnosis. The impact is more pronounced in mothers, especially mothers of children diagnosed in preschool years. And these findings come from a European study.. not the US. Previous research has shown that parents of children with type 1 diabetes are at increased risk of stress-related symptoms and may need to reduce their working hours. "In our study, we observed reduced parental work-related incomes in the years following the child's type 1 diabetes diagnosis. The drop was larger in mothers than in fathers. Since mothers earned significantly less than fathers in absolute terms, even before the child fell ill, the relative drop in mothers was 6.6% the year following diagnosis compared to 1.5% in fathers. We further note the greatest impact on work-related incomes in mothers of children diagnosed at preschool age," says Beatrice Kennedy, physician at the Endocrine and Diabetes unit at Uppsala University Hospital and Associate Professor of Medical Epidemiology at Uppsala University, who led the study. This is a huge study, builds on data from national population and health registers and the Swedish Child Diabetes Register (Swediabkids). The study includes the parents of more than 13,000 children diagnosed with type 1 diabetes in Sweden in 1993−2014, as well as more than half a million parents in the general population who have children not diagnosed with diabetes. The researchers observed that the maternal pension-qualifying incomes (a composite outcome including work-related income and societal benefits) initially increased after the child's diagnosis. This was attributable to mothers applying for the parental care allowance from the Swedish Social Insurance Agency. The parental care allowance was intended to compensate for disease-related loss of work-related income and contribute toward disease-specific costs. When the research team investigated long-term effects in mothers, they found that the pension-qualifying incomes gradually decreased after eight years, and had not recovered by the end of follow-up − 17 years after the children were diagnosed. XX The U.S. Department of Justice has reached a settlement with Metro Nashville Public Schools after allegations that the district violated the Americans with Disabilities Act. The parents of a student at the Ross Early Learning Center requested that the school monitor their child’s glucose monitor. Investigators found the school refused to do so, despite the child’s Type 1 Diabetes diagnosis. As part of the settlement, MNPS agreed to change its policies to allow the use of these devices, ensure trained staff can monitor them throughout the entire school day and at school activities, and improve communication with parents. XX Modular Medical has unveiled Pivot, its next-generation insulin patch pump technology aimed at simplifying diabetes care. The company announced its new pump for “almost-pumpers” at the Association of Diabetes Care & Education Specialists (“ADCES”) Conference in Phoenix, Arizona this weekend. It aims for Pivot to target adults with a user-friendly, affordable design. Modular Medical’s current pump, the MODD1, won FDA clearance nearly a year ago. It features new microfluidics technology to allow for the low-cost pumping of insulin. The system has a reservoir size of 300 units/3mL. Users can monitor the pump activity with their cell phone and do not require an external controller. The pump uses a provided, single-use, disposable battery. The company announced recently that it validated its insulin pump cartridge line for human-use production in the U.S. Days later, it reported the first human use of the MODD1 pump. Now, it has taken the next steps with the debut of a next-gen pump, set for FDA submission in October. Modular Medical also gamifies diabetes care The company also said ADCES is the place where it will showcase the first playable level of its new Pivot pump gamified trainin module. Level Ex, a developer of medical games, develops the module. Modular Medical said gamification offers a way to make medical training more effective and efficient while improving information retention. Given the complexity in pump uptake, the company hopes to provide an easy way to bring its technology to clinicians and patients. The company expects to have training modules available at the same time as the pump’s planned launch in 2026. “Level One is free because diabetes mastery shouldn’t come with a price tag,” Sam Glassenberg, CEO of Level Ex, said. “Modular Medical is breaking barriers too – bringing pump therapy to more people through smart, accessible design. Together, we intend to make diabetes management simpler and more inclusive. “People learn best through play – and we believe they want to learn about insulin pumps the same way. In Level One, players aren’t just mastering diabetes management through gameplay – they’re asking to ‘play’ with pumps: to explore how they work, understand their benefits, and build confidence before using them in real life. Our partnership with Modular Medical helps make that possible.” XX On Tuesday, 12 August 2025, Tandem Diabetes Care (NASDAQ:TNDM) presented at the Canaccord Genuity’s 45th Annual Growth Conference, outlining strategic shifts and market focus. The company highlighted its plans for commercial transformation in the U.S. and expansion in international markets, alongside addressing competitive challenges and regulatory impacts. While optimistic about growth in Outside the U.S. (OUS) markets, Tandem is navigating a more competitive landscape domestically. We have entered into the pharmacy channel with Mobi only. And so as Mobi’s been building up volume, we’re getting experience and we’re really learning and understanding what pharmacy offers to us. And the proof points have proved out the thesis I said earlier, which is it can really reduce that barrier for patients, is the out of pocket cost. And so we’ve decided to accelerate our strategy and where we were starting just with Mobi, we are now moving t slim supplies into the pharmacy channel, and that will kick into gear in the fourth quarter. So as people are looking at the cadence of sales for the remainder of the year with this reframing, many folks are seeing what looks like a a might be an outsized fourth quarter and and having trouble understanding those dynamics. We’ll be adding the tSIM supplies to those contracts. We also have more coverage. We will have it in the coming weeks effective this year, so we will be increasing that 30% rate before the end of the year. And then, obviously, everyone’s in the same cycle right now already negotiating and discussing their 2026 coverage. And so 30% is the floor. We do expect to continue to grow that coverage in the coming years, and ultimately have a much broader access. Absolutely. It’s an exciting technology that allows for us to have an infusion set that extends the wear time from three days to up to seven days. So we’re able to use that as part of an independent infusion set, which would then be used with the t slim and with the mobi pump today. But we’re also using that same technology as part of the site that’s used for mobi when you use it with a tubeless cartridge. So next year, we will launch Mobi in a patch configuration. It uses the same pump that’s available today, but by using a modified cartridge, you’re able to wear it as a patch pump. So one of the things we announced on the call is that we’re using this extended wear technology as part of that site. So what it allows you to do is to change the portion that you wear in your skin separate from the timing of when you change the insulin cartridge. So it allows for that extended wear time, reduction of burden to the patient, which is especially important for higher volume insulin users as we expand into type two. So from here, we will launch the extended wear site next year along with we’ll do a separate regulatory filing for the cartridge portion for Mobi that includes this extended wear technology as a predicate device. So that’s another filing that we’ll need to do, but we have the clearance today for the independent infusion set, but we’ll file another five ten k for use of the extended wear technology as part of the tubeless Mobi feature. https://za.investing.com/news/transcripts/tandem-diabetes-at-canaccord-conference-strategic-shifts-and-market-focus-93CH-3834464 XX MannKind today announced a significant regulatory submission and a large financing agreement with Blackstone. The company submitted its lead inhaled insulin product for expanded FDA approval and secured $500 million in funding, it said. First, the Danbury, Connecticut-based company announced that it submitted a supplemental Biologics License Application (sBLA) for Afrezza, its inhaled insulin product, in the pediatric population. MannKind Director of Medical and Scientific Engagement Joanne Rinker, MS, RDN, BC-ADM, CDCES, LDN, FADCES, told Drug Delivery Business News at ADA 2025 that a submission was on the way for children and adolescents aged 4-17 years old. Further data shared at ADA found Afrezza both safe and effective in that age range. Afrezza is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical inhaler device to slowly bring powder into the lung. A small compartment opens for the insertion of the insulin cartridge, then the user closes it. The only other component is a mouthpiece for the sake of cleanliness. Then, the inhalation takes just two seconds. It requires no electronics or extra components. The company expects a review acceptance decision early in the fourth quarter of 2025. “The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes,” said Michael Castagna, CEO of MannKind Corporation. Additional funding provides a significant boost for MannKind MannKind also announced a strategic financing agreement with funds managed by Blackstone worth up to $500 million. The financing provides MannKind with non-dilutive capital to advance its short- and long-term growth strategies. This senior secured credit facility includes a $75 million initial term loan funded at closing. It then has a $125 million delayed draw term loan available for the next 24 months. Finally, it features an additional $300 million uncommitted delayed draw term loan available at the mutual consent of MannKind and Blackstone. The facility bears interest at a calculated SOFR variable rate plus 4.75% and matures in August 2030. “This strategic financing significantly increases our operating flexibility and provides us substantial access to non-dilutive capital on favorable terms, complementing our strong cash position,” said Castagna. “The funding will support the expansion of our commercial team in preparation for the anticipated launch of the pediatric indication for Afrezza, if approved, continued pipeline advancement, potential business development opportunities, and general corporate purposes. Partnering with the Blackstone team on this transaction positions us to accelerate our next phase of growth and innovation.” https://www.drugdeliverybusiness.com/mannkind-fda-submission-pediatrics-500m-blackstone/ XX Medtronic MiniMed Abbott Instinct Sensor [Image from Medtronic Diabetes on LinkedIn] The Medtronic Diabetes business today took to social media to share an early preview of a new integrated Abbott sensor for its insulin delivery systems. Medtronic Diabetes — soon to be MiniMed after its planned separation from the medtech giant – said in the post that the new sensor specifically designed for its own systems is called “Instinct.” “Get a sneak peek at what’s coming next: the Instinct sensor,” the business unit’s account wrote. “Made by Abbott, the Instinct sensor is...
/episode/index/show/diabetesconnections/id/37815675
info_outline
Ketones: preventing DKA now and hope for the future of monitoring
08/12/2025
Ketones: preventing DKA now and hope for the future of monitoring
We’re all supposed to know about ketones, but how much education did you actually get? I’m talking to Dr. Jennifer Sherr, a pediatric endocrinologist who lives with type 1 about the basics of ketones and a lot more. She shares best practices to stay safe, what most people with diabetes really do and what she’s hopeful for in terms of making ketone monitoring easier. We’ve been managing T1D for 18 plus years and I was surprised, there was still a lot here I didn’t know. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us for a Join us at Learn more about Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: info@diabetes-connections.
/episode/index/show/diabetesconnections/id/37759705
info_outline
Peloton’s Robin Arzón on T1D Screening Plus: The Science Behind Tzield
08/05/2025
Peloton’s Robin Arzón on T1D Screening Plus: The Science Behind Tzield
We're diving into the first-ever treatment that can delay the onset of type 1 diabetes—Tzield—and hearing from two powerful voices helping spread the word about screening. First, Peloton star Robin Arzon shares her personal journey - managing diabetes through marathons, pregnancy, and parenting—and why she believes time and information are two of the most valuable tools in diabetes care. Robin is VP of Fitness Programming and Head Instructor at Peloton, 27x marathoner, Swagger Society Founder, best-selling author, and Sanofi spokesperson We're also going to learn more about Tzield itself from Dalila Masic, PharmD: Field Medical Director, T1D Immunology at Sanofi. We're talking about how this works now, who its for, and the future of prevention. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More Robin Join us at Learn more about Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: info@diabetes-connections.
/episode/index/show/diabetesconnections/id/37648280
info_outline
In the News.. A new insulin approved, DOJ rules on CGM in schools, T2D artificial sweetener study, and more!
08/01/2025
In the News.. A new insulin approved, DOJ rules on CGM in schools, T2D artificial sweetener study, and more!
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: FDA approves the first fast-acting biosimilar insulin in the US, Tandem issues warning, DOJ stands up for remote monitoring in schools, GLP1 use protects against dementia, and more! Find out more about Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX We’ve got the first and only biosimilar FDA approved and moving to market. Kirsty – insulin aspart, which is a biosimilar to Novolog will be available as a single-patient-use prefilled pen for subcutaneous use and a multiple-dose vial for subcutaneous and intravenous use. KIRSTY has been available in Europe and Canada since 2022. This same company makes Semglee, the first biosimilar for long acting? Sales of Insulin Aspart in the United States were approximately $1.9 billion in 2024, according to IQVIA. https://www.globenewswire.com/news-release/2025/07/15/3115973/0/en/Biocon-Biologics-Expands-Diabetes-Portfolio-with-FDA-Approval-of-Kirsty-the-First-and-Only-Interchangeable-Rapid-Acting-Insulin-Aspart-in-the-United-States.html XX Tandem Diabetes Care (Nasdaq:TNDM) has issued an urgent medical device correction for some t:slim X2 automated insulin pumps. In a July 22 notice, the San Diego-based company warned of pumps that may exhibit a higher rate of speaker failure. During normal use, the insulin pump software monitors current flowing through the speaker during use. Measurements that fall within a pre-determined range indicate a functioning speaker. Meanwhile, measurements falling outside the range indicate a speaker failure. When the measurements land outside the expected range, the system declares a malfunction, referred to as “Malfunction 16.” If the pump declares this malfunction, insulin delivery will stop and the pump will no longer be operational. Malfunction 16 terminates communication between the pump and continuous glucose monitor (CGM), as well as the t:slim mobile app. If not addressed, the issue can lead to hyperglycemia, which can result in hospitalization or medical intervention. The company reports 700 adverse events and 59 reported injuries to date, with no reports of death. Tandem identified that certain speaker versions have a higher rate of Malfunction 16 events due to a wiring issue within the speaker. Users can continue using their pump but with added precautions because Malfunction 16 can occur at any time. They should use the t:slim mobile app with push notifications turned on so the app alerts them if the malfunction occurs, the company said. Additionally, Tandem intends to release a software update aimed at enhancing the early detection of speaker failure. The update also introduces persistent vibration alarms to help reduce potential safety risk. Tandem plans to notify affected pump users when it makes the update available. https://www.drugdeliverybusiness.com/tandem-warns-insulin-pump-speaker-malfunction/ XX BIG WIN! The DOJ protects T1D rights again! The US Attorney's office for the Western District of Washington State reached a settlement with a public school district that once again confirms remotely monitoring students’ CGMs is a reasonable accommodation that schools must provide to comply with the Americans with Disabilities Act. If its true for one state its true for all states under federal law! If your local schools still refuse to remotely monitor CGMs of their students, provide them with this letter to compel them to FOLLOWT1Ds and FOLLOW Federal Laws. If they still refuse contact us! https://followt1ds.org/ XX new study finds people taking GLP-1 agonists had a significantly lower cumulative risk of developing dementia, when compared to metformin users. Past studies show that people who have type 2 diabetes — a chronic condition where the body does not use its insulin properly — are at a higher risk of developing dementia. The study found that when comparing the neuroprotective abilities of two diabetes medications — metformin and glucagon-like peptide-1 receptor agonists (GLP-1 agonists) — participants taking GLP-1 agonists had a significantly lower cumulative risk of developing dementia, when compared to metformin. XX Front office changes coming to Dexcom. CEO Kevin Sayer will step down & give the reins to current Chief Operating Officer Jake Leach. Scheduled for January 1, 2026, Leach will also join Dexcom’s board of directors where Sayer will remain executive chairman. One of our frequent guests here.. Leach has worked at Dexcom for 21 years. He served as chief technology officer from 2018 to 2022 before he was named COO in late 2022. He was given the title of president in May. https://www.medtechdive.com/news/dexcom-ceo-change-kevin-sayer-jake-leach/756382/ XX A major international study has revealed that many children and young adults in Sub-Saharan Africa who are diagnosed with type 1 diabetes (T1D) may actually have a different, non-immune-based form of the condition. Unlike the traditional autoimmune version of T1D, this form appears to develop without the immune system attacking the insulin-producing cells. This finding could significantly reshape how diabetes is diagnosed and treated across the region, potentially leading to more precise care and better health outcomes. The researchers found that many young people in Sub-Saharan Africa diagnosed with T1D often don’t have the usual markers in their blood (called islet autoantibodies) typically seen in people with T1D in other parts of the world. Specifically, 65% of participants with T1D in this region did not have islet autoantibodies. When the researchers compared this data to studies in the U.S., they found a smaller but significant proportion (15%) of Black participants diagnosed with T1D had a similar form of diabetes found in Sub-Saharan Africa – characterized by negative autoantibodies and a low T1D genetic risk score. However, white Americans with T1D showed the typical autoimmune pattern, even if they didn’t have detectable autoantibodies, their genetics still pointed to autoimmune diabetes. “The identification of this T1D diabetes subtype in Sub-Saharan African populations and among individuals of African ancestry in the U.S. suggests a potential ancestral or genetic link,” Dabelea notes. “These findings highlight the need to consider alternative etiologies in this group and a deeper understanding of the underlying mechanisms may provide important insights for future prevention and treatment strategies.” XX Formal recognition for the specialty of Diabetology. Diabetology is the specialty focused on the full continuum of diabetes care — encompassing diagnosis, treatment, prevention, technology integration, education, and cardiometabolic management. While it intersects with endocrinology, primary care, and public health, diabetology is uniquely defined by its depth and focus on diabetes alone. The American College of Diabetology (ACD) is the national professional organization representing clinicians who specialize in diabetes care. ACD advances clinical excellence and education to improve the lives of those affected by diabetes. XX Tidepool announces cloud-to-cloud integration with Abbott’s FreeStyle Libre portfolio. From the release: This integration allows people living with diabetes using the FreeStyle Libre portfolio to connect their data to their Tidepool account seamlessly. For healthcare providers, this means more comprehensive insights and streamlined workflows, with FreeStyle Libre systems data flowing continuously into the Tidepool Data Platform. XX Stelo dexom ai food XX With high drug prices remaining an ongoing concern for U.S. politicians, Roche is considering following in the footsteps of some of its peers with a direct-to-consumer (DTC) model to cut out the middlemen. About 50% of the money spent on drugs in the U.S. healthcare system goes straight to PBMs instead of the companies that create the medicines, Roche CEO Thomas Schinecker called out in a press conference on Thursday. Bringing the drugs directly to the consumer could be a solution to positively impact pricing for patients “without destroying innovation,” Schinecker added on a separate Thursday call with investors, noting that the company has discussed the matter with the U.S. government and its Department of Health and Human Services. The pricing talks come after President Donald Trump inked a “Most Favored Nation” executive order in May, aiming to tie U.S. drug prices to lower prices in other developed nations. The plan was quickly called out by industry voices such as the PhRMA trade group, which labeled it a “bad deal” for U.S. patients. XX SAB BIO secures substantial $175M financing to advance T1D therapy with impressive investor lineup and extended cash runway until 2028. Most critically, this financing fully funds the pivotal Phase 2b SAFEGUARD study evaluating SAB-142 for delaying progression of autoimmune Type 1 diabetes in newly diagnosed patients. By extending the cash runway into mid-2028, SAB has effectively eliminated near-term financing risk and provided clear visibility through this crucial clinical trial and potential commercialization preparation. Participation from strategic investor Sanofi, along with new investors RA Capital Management, Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce Street Capital, Forge Life Science Partners and Woodline Partners LP, and existing investors Sessa Capital, the T1D Fund, and ATW Partners XX In a landmark 14-year study, researchers have found that artificially sweetened drinks raise the risk of developing type 2 diabetes by more than a third, significantly higher than those loaded with sugar. It challenges the long-standing perception of diet drinks being a healthier alternative and suggests they may carry metabolic risks of their own. In the first longitudinal study of its kind, led by Monash University, researchers tracked 36,608 participants over an average period of 13.9 years to assess how both sugar-sweetened beverages (SSBs) and artificially sweetened beverages (ASBs) impacted health outcomes. The self-reported health data, from the Melbourne Collaborative Cohort Study, was drawn from participants aged 40 to 69 years at the time of recruitment. What they found was that drinking just one can of artificially sweetened soda increased the risk of developing type 2 diabetes by 38%, compared to people who didn’t consume these drinks at all. For those consuming the same amount of sugary drinks, the risk was 23% higher. This suggests there's more than obesity at play. The researchers believe this result is due to an independent metabolic effect, possibly gut microbiome disruption or a change in glucose metabolism. While the study didn't identify which artificial sweeteners were at play, Evidence suggests that artificial sweeteners can alter the composition and function of gut bacteria, leading to glucose intolerance – a precursor to type 2 diabetes. And that some sweeteners may trigger insulin release, desensitize metabolic responses over time, or confuse the body’s glucose regulation system – even without actual sugar in the picture. Another hypothesis is that regular exposure to the kind of intense sweetness that artificial products deliver may condition the body to anticipate sugar calories that never come, affecting appetite regulation, insulin sensitivity and broader metabolic pathways. However, the authors suggest that how sweeteners affect the gut microbiota and glucose regulation are the most likely drivers of increased diabetes risk. XX After months of deliberation, information gathering and public testimony, a state board unanimously agreed Monday that two common medications for type-2 diabetes and other conditions appear to pose an affordability challenge to the state and Marylanders. The state Prescription Drug Affordability Board approved two resolutions saying that prescription drugs Jardiance and Farxiga likely pose an “an affordability challenge for the state health care system” and the state should look for ways to bring down those costs. Health care advocates call the long-awaited resolution an “important first step” in the process in bringing down prescription costs for those on the state’s health plan. That milestone has been years in the making. Created in 2019 by the General Assembly, the Prescription Drug Affordability Board was slow to launch due in part to a veto from former Gov. Larry Hogan (R) amid pandemic-induced economic uncertainty in 2020 that delayed the board’s formation. The board also cited out-of-pocket costs for consumers and state and local spending on those drugs as indicators that there may be an affordability challenge. The board will now look at options to address the potential affordability challenge, which could include setting an upper payment limit on those drugs. But it’s not clear when the state will see cost savings. That said, some members of the health care system and the pharmaceutical industry say that policies such as upper payment limits could weaken access to life-saving drugs. Others say that the board has not engaged enough viewpoints from the health care industry. XX One year after it was revealed that Chrissy Teigen and John Legend’s son, Miles, was diagnosed with type 1 diabetes, Teigen is revealing how she’s making her son feel more included. Teigen first opened up about her 7-year-old son’s diagnosis after she and her two oldest kids, Miles and 9-year-old daughter Luna were at the 2024 summer Olympics cheering on Simone Biles. Teigen posted a photo of Miles and Luna holding up a sign. Also visible in the picture was the insulin pump on Miles’ arm. Now, Teigen is sharing some insight into how she’s making Miles more comfortable with having type 1 diabetes, including giving LeBron James’ Barbie doll type 1 diabetes as well. In a video shared on Instagram, Teigen is seen taking the T1D Barbie, removing her insulin pump and gluing the pump onto LeBron James’ Barbie. “Turning T1D Barbie into T1D Lebron James for my son,” Teigen captioned the video, revealing James is Miles’ hero. 41 million followers https://www.yahoo.com/lifestyle/articles/chrissy-teigen-gives-lebron-james-154608782.html
/episode/index/show/diabetesconnections/id/37620150
info_outline
T1D pregnancies deserve better research: this study targets the gaps
07/29/2025
T1D pregnancies deserve better research: this study targets the gaps
Pregnancy with type 1 diabetes requires tight management—but what if the very tools designed to help aren't designed or approved for pregnancy? We’re talking about the T1D Pregnancy & Me study, a groundbreaking effort to close the data gap and include pregnant women in diabetes tech research. We’ll go through who can be in this study, how It works, what they’re looking for and what it could mean for the future of diabetes care during those nine months and a lot more. My guests are: Dr Camille E. Powe, an Associate Professor at Massachusetts General Hospital and Harvard Medical School and the study’s Chair and Carrie Matuzsan, a patient advisor. Carrie lives with type 1 and had twins in 2020. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Learn Join us at Learn more about Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: info@diabetes-connections.
/episode/index/show/diabetesconnections/id/37532900
info_outline
Managing type 1 diabetes at 200 MPH: Conor Daly on Racing, Resilience, and Inhalable Insulin
07/22/2025
Managing type 1 diabetes at 200 MPH: Conor Daly on Racing, Resilience, and Inhalable Insulin
Managing type 1 when your job means you burn more than 5-thousand calories and lose 10 pounds of water in one day is.. a little different. I caught up with IndyCar driver Conor Daly who is in the middle of the season right now! Diagnosed at 14, Conor talked to me about continuing to chase his dreams of racing, using inhaled insulin – Afrezza – as part of his T1D management for a long time now, how he deals with diabetes during races, and a lot more. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at Learn more about Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: info@diabetes-connections.
/episode/index/show/diabetesconnections/id/37472320
info_outline
In the News: Sernova transplant update, at-home T1D test moves forward, best diet for T2D, Mattel releases type 1 barbie and more!
07/18/2025
In the News: Sernova transplant update, at-home T1D test moves forward, best diet for T2D, Mattel releases type 1 barbie and more!
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Sernova has a new partner and a new drug for cell transplants, at home glucose/T1D test research, study looks at best diet for people with type 2, Lifescan files for banktrupcy, T1D Barbie and more! Find out more about Read (and send me yours!) Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: Episode transcription with links: In the News July 18 Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Sernova is partnering with Eledon Pharmaceuticals to test a new immunosuppressive drug in its ongoing clinical trial for people with type 1 diabetes (T1D). The drug called tegoprubart is designed to protect transplanted islet cells without harsh side effects. The current treatment is known for its potential toxicity, especially towards insulin-producing beta cells, and its adverse side effects, making it less than ideal for islet cell therapy in T1D. Tegoprubart has already shown promise in earlier trials, helping T1D patients achieve insulin independence with better graft survival and fewer side effects. This next phase of Sernova’s trial (Cohort C) will combine Eledon’s drug with Sernova’s Cell Pouch, an implantable device that houses insulin-producing cells. In earlier phases, six participants stopped needing insulin completely, with results lasting years. Sernova also plans to use stem cell-derived islet-like clusters from partner Evotec to create a next-gen therapy. If all goes well, a new clinical program could launch in 2026. https://www.streetwisereports.com/article/2025/07/15/biotech-partnership-to-revolutionize-diabetes-treatment.html XX Researchers at Yale School of Medicine, funded by Breakthrough T1D, are evaluating GTT@home, a new finger-prick, at-home glucose tolerance test, to monitor early-stage type 1 diabetes (T1D) in individuals with T1D autoantibodies. Developed by Digostics (Dih-jos-tiks), the test offers a simpler, less invasive alternative to clinic-based oral glucose tolerance tests. The study aims to assess its accuracy, usability, and acceptance, potentially paving the way for wider use in early T1D detection and monitoring. The results of the trial will inform future regulatory submissions for GTT@home use in T1D, which already has regulatory approval in the UK, Europe and other regions for other types of diabetes. https://finance.yahoo.com/news/digostics-announces-university-trial-home-164300142.html XX announced that it entered into a restructuring support agreement and, to implement it, filed for chapter 11 bankruptcy. As the process moves forward, LifeScan plans to operate in the ordinary course of business. It expects to emerge from chapter 11 by the end of the year. that provide simplicity, accuracy and trust in diabetes management. XX New study looks at quality of life and cost of AID systems. This was done in Finland which has the highest prevalence of T1D in the world. The results show automated insulin delivery pumps significantly improved quality of life and reduced diabetes-related complications. The quality-adjusted life expectancy increased by an average of 2.3 years for individuals using an automated insulin delivery pump. Although the overall costs of automated insulin delivery pump treatment were higher than those of conventional insulin pump treatment, its cost-effectiveness ratio was well below the generally accepted willingness-to-pay threshold of 50,000 euros in Finland. This is the first cost-effectiveness study of automated insulin delivery pumps conducted in Finland. XX expands into the 11th state: Louisiana! This is Free, comprehensive virtual clinical care, education, and support program for adults with type 1 diabetes In addition to serving adults with type 1 diabetes in Louisiana, our program is also active in Alabama, Mississippi, Florida, Missouri, Iowa, Ohio, Vermont, New Hampshire, Maine, and Delaware. The program serves as an extension of participants' existing care teams and ensures continuity of care The organization hopes to inform new care models and policies that remove barriers to healthcare People with T1D over 18 years of age who speak English or Spanish are eligible to enroll. To sign up directly, refer a person living with T1D, or learn how you can partner with Blue Circle Health, visit www.bluecirclehealth.org. XX A new study comparing three popular diets—intermittent fasting, time-restricted eating, and continuous calorie cutting—found that all can help people with type 2 diabetes lose weight and lower blood sugar. But one diet stood out: the 5:2 intermittent fasting plan, where participants eat normally five days a week and restrict calories on two. It led to better results in fasting blood sugar, insulin response, and sticking with the plan. Although researchers identified improved HbA1c levels, and adverse events were similar across the three groups, the IER group showed greater advantages in reducing fasting blood glucose, improving insulin sensitivity, lowering triglycerides, and strengthening adherence to the dietary interventions. XX MIT students have developed an implantable device.. for use during emergency low blood sugars. The new implant carries a reservoir of glucagon that can be stored under the skin and deployed during an emergency — with no injections needed. The researchers showed that this device could also be used to deliver emergency doses of epinephrine, a drug that is used to treat heart attacks and can also prevent severe allergic reactions, including anaphylactic shock. The device contains a powdered form of glucagon and can be remotely triggered—either manually or automatically by a glucose monitor—to release the hormone when blood sugar drops too low. No word on next steps to make this commercially available. XX We’ve covered T1D1 before, this is an insulin calculator app – there’s more to it than that.. it was created by 13 year old Drew who lives with type 1, but removed from the apps stores a few years ago, along with other non fda cleared apps. Drew who is now 18, Tells us they just submitted to the FDA and are optimistic about being reinstated. https://www.instagram.com/t1d1app/ XX XX 1’m Brodie Sargent, a Type 1 diabetic raised in Mudgee, NSW, and currently living in Wollongong. Starting August 26th, I’ll be running a marathon every day for 26 days, and on the 27th day, I’ll be finishing with Western Sydney’s Half Ironman. The current world record for the most consecutive marathons run by a Type 1 diabetic male is 25 and I’m aiming to break it. I’m doing this to inspire others, diabetic or not, to challenge themselves and not let anything hold them back. Any donation is greatly appreciated and supports a cause I truly believe in. The Type One Foundation focuses on support, connection, awareness, and advocacy for diabetics across Australia. They run online and in-person events for diabetics and their families, and also offer care packages to those newly diagnosed. I was diagnosed at 15, and it was a tough time for me and my family, we had no history or understanding of diabetes. I was already a shy and awkward kid, and I struggled to speak up about how much it affected me. I started running with my roommate just to kill time but it quickly took over my life. Feeling stuck and unsure where I was heading, I decided to make a change and try to help anyone out there feeling the same way. You can follow my journey on Instagram: @typerun_ XX Launched during children’s congress To further promote inclusivity and tackle the stigma associated with the condition, Mattel partnered with Breakthrough T1D, a global organization dedicated to type 1 diabetes research and advocacy, to launch its first Barbie with type 1 diabetes. This partnership marks a major milestone in Mattel’s commitment to greater representation, and highlights Breakthrough T1D’s pivotal role in ensuring visibility for the type 1 diabetes community. The doll is part of the Barbie Fashionistas line and includes key diabetes management tools modeled accurately with the help of Breakthrough T1D. The type 1 diabetes Barbie wears a continuous glucose monitor (CGM) secured with Barbie-pink, heart-shaped tape, and has an insulin pump at her waist. She also comes with a CGM-tracking smartphone, a pastel blue purse, and a blue polka dot outfit – blue being the color that symbolizes global diabetes awareness. As part of a broader initiative to elevate voices in the type 1 diabetes community, Barbie also partnered with two global role models living with type 1 diabetes: Peloton Instructor Robin Arzón and model Lila Moss. Robin Arzon Barbie Image Credit: Breakthrough T1D and Mattel Mattel’s one-of-a-kind doll based on Arzón features her signature yellow outfit and a crown-shaped CGM on the back of her arm. In interviews, Moss has highlighted the positive impact that the type 1 diabetes Barbie’s visibility has already had, saying she receives daily messages from young people who feel less insecure about wearing their diabetes devices thanks to her public advocacy. When Linxi Mytkolli, director of patient engagement at Diabetes Action Canada and person with diabetes, heard about the new “Dia Barbie,” she said she teared up. “I grew up loving dolls, but I never saw one that reflected the reality I now live with – until Dia Barbie. Seeing a doll with a CGM, insulin pump, and even heart-shaped medical tape felt surreal. It’s playful, powerful, and personal all at once,” said Mytkolli. Mytkolli also emphasized that representation and visibility in toys and media can help chip away at shame. “I’ve heard from so many people, especially those diagnosed in childhood, who delayed using tech like pumps or CGM because it felt like a punishment. Visibility in toys helps normalize these devices and makes kids feel like they're not alone or ‘othered.’ It turns stigma into something softer – something that can be talked about, shared, even celebrated,” Mytkolli said. And its impact goes beyond people living with diabetes. Laura Pavlakovich, who is the founder and CEO of You’re Just My Type and has lived with type 1 diabetes since age five, shared that this representation is equally crucial for those without diabetes, as it demystifies the condition and challenges stereotypes. “This kind of representation builds a vital bridge of empathy, illustrating that living with diabetes is simply a part of life for millions. It's an essential tool for educating the public and cultivating a more inclusive and supportive society for everyone,” said Pavlakovich. Pavlakovich shared her personal experience of growing up with diabetes and how this will provide validation for those with the condition who often feel unseen. “I vividly remember growing up with a 'my twin' doll, custom-made to look just like me, yet she always lacked the crucial part of my daily reality: an insulin pump. To finally see a Barbie, an iconic figure in childhood play, accurately depict someone living with type 1 diabetes, complete with her devices and pump, is truly a monumental moment,” said Pavlakovich. To celebrate the launch, Barbie donated dolls to the Breakthrough T1D 2025 Children’s Congress in Washington, D.C., where 170 young advocates for type 1 diabetes from around the world met with lawmakers to raise awareness. Priced at $10.99, the doll is now available on Mattel Shop and at retailers nationwide. While this is a huge win for enhancing the representation of children living with diabetes, it doesn’t end there. There is still significant work to be done to improve access to diabetes medication and technology. “It is not lost on me that Barbie has more access to diabetes tech than many, if not most, people with diabetes globally,” said Mytkolli. “Representation and access – we deserve both.” By bringing a common but misunderstood condition into children’s toy boxes, the new type 1 diabetes Barbie is more than a toy. It’s a symbol of pride, visibility, and the message that children with diabetes can live full, empowered lives. As Mytkolli said, “Whether a child is living with diabetes, or loves someone who is, this doll quietly says, ‘You’re not broken. You belong.’”
/episode/index/show/diabetesconnections/id/37448545
info_outline
“I love to change people’s minds” - My son, Benny, on 18+ years of T1D
07/15/2025
“I love to change people’s minds” - My son, Benny, on 18+ years of T1D
Benny’s back! My son – diagnosed with type 1 at age 2 and now 20 years old – joins me to talk about what’s new in his diabetes management. He’s made some big changes, including using U-200 insulin and just starting on a GLP-1. We’ll talk about what led to those decisions and the effects they’ve had. We’ll have an update on the Follow situation, Benny’s experience training as an EMT, and how he’s feeling after 18 years of type 1. Spoiler: if I could bottle how relaxed & confident this kid is, I would really have something. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Previous Join us at Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: info@diabetes-connections.
/episode/index/show/diabetesconnections/id/37403985
info_outline
It’s Personal: Why this Pediatric Endo is making the case for T1D screening
07/08/2025
It’s Personal: Why this Pediatric Endo is making the case for T1D screening
Screening has moved front and center in the conversation around type 1 diabetes. But we’re just at the very beginning of this – what do we really need to know? I’m talking to Dr. Shara Bialo – she’s a pediatric endocrinologist who lives with type 1. She was diagnosed as a kid while in DKA. She’s working with Sanofi to push for screening, but this is personal – we talk about wanting better guidelines, and more mental health support. And how do we move this research into the general population, where it can have the greatest impact? More This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Previous Join us at Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: info@diabetes-connections.
/episode/index/show/diabetesconnections/id/37333990
info_outline
What’s ahead for Tandem Diabetes? An update on pumps, CGMs, infusion sets, and more!
07/01/2025
What’s ahead for Tandem Diabetes? An update on pumps, CGMs, infusion sets, and more!
This week on Diabetes Connections, Tandem Diabetes made some big announcements at the recent ADA Conference – we’re going behind the headlines and asking your questions about Control IQ updates, extended wear infusion sets, what’s happening with their patch pumps, and a lot more. I’m talking to Ben Mar the Director of Product marketing. We also getting into their expanded partnership with Abbott – in additional to the Libre 3 plus, they’re one of the pump companies that has signed on for the future glucose/ketone sensor. A lot to get to here! This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Previous Join us at Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: info@diabetes-connections.
/episode/index/show/diabetesconnections/id/37218000
info_outline
In the News...Top Stories from ADA and more!
06/27/2025
In the News...Top Stories from ADA and more!
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: loads of news from American Diabetes Association Scientific Sessions, GLP1 for T1D, Tech updates, diabetes in space, and more! Find out more about Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Top story – looking back at The American Diabetes Association Scientific Sessions conference. I won’t recap everything here – but I’ll link up to a few more comprehensive article. Here’s just a taste! XX A single infusion of a new stem cell-based treatment helped 10 out of 12 people with severe stop using insulin, researchers report. The treatment, called zimislecel, was made by Vertex Pharmaceuticals. It’s an infusion of lab-grown islet cells. A year after getting the therapy, 10 patients no longer needed insulin shots. The other two were able to reduce how much insulin they needed. The treatment requires patients to take immunosuppressive drugs, which may raise the risk of infections or cancer in the long run, experts said. https://www.usnews.com/news/health-news/articles/2025-06-24/stem-cell-treatment-may-free-some-with-type-1-diabetes-from-insulin XX New study shows inhaled insulin is safe and effective for children with type 1 diabetes. This is Mannkind’s Afrezza, which takes the place of rapid-acting mealtime insulin. Findings indicate that inhaled insulin delivers glycemic control comparable to injected rapid-acting insulin. Inhaled insulin was also associated with less weight gain and slightly higher patient and parent preference scores. These findings add to . Based on the findings of the inhaled insulin study, MannKind looks to seek FDA approval to expand Afrezza’s indication to children. The company also aims to evaluate inhaled insulin at diagnosis and in automated insulin delivery systems in additional studies. https://www.drugdeliverybusiness.com/study-mannkind-inhaled-insulin-safe-effective-children/ XX Positive outcomes in two different studies looking at GLP 1 medications for type 1. Semaglutide – brand name Ozempic or Wegovy - reduced glucose levels and weight among patients with type 1 diabetes and obesity. 26-week, double-blind trial of 72 adults, those taking Ozempic spent More than 70% time spent in sensor glucose range (70-180 mg/dL) Less than 4% time spent in hypoglycemia (<70 mg/dL) At least 5% body weight reduction Although none of the GLP-1 receptor agonists are approved for type 1 diabetes -- largely due to safety concerns about hypoglycemia and diabetic ketoacidosis -- Shah that showed increasing off-label use in this population. Half of the patients in the semaglutide group achieved an HbA1c level below 7% at 26 weeks compared with 22.2% of those in the placebo group. Semaglutide patients also had greater weight loss (least-squares mean group difference -8.8 kg [19.4 lb]). As for adverse events of special interest for a type 1 diabetes population, rates of severe hypoglycemia were low (5.5% vs 5.5%) and no cases of diabetic ketoacidosis occurred. https://www.medpagetoday.com/meetingcoverage/ada/116206 XX Tirzepatide – brand name Monjourno or Zepbound has demonstrated promising safety and efficacy in people with type 1 diabetes (T1D) in new data from a longitudinal, retrospective study.1 after 3 months, participants experienced a significant 6.7 kg reduction in mean weight (95% CI, 5.4-8.0 kg; P <.001; n = 36) and were able to reduce mean total daily insulin dose by 21.6 units (95% CI, 12.8-30.4; P <.001; n = 28), mostly driven by reduction in bolus doses (95% CI, 14.4 units; 6.6-22.2; P = .001; n=26.) Furthermore, time in range (70-180 mg/dl) also significantly increased from 54.9% to 60.8% (95% CI, 0.0-11.8; P = .048l; n = 36).1 “In people with T1D and obesity, there's quite a lot of off label GLP-1 agonist use and tirzepatide, as a proportion of that, is increasing,” Berry told HCPLive. “People found it really beneficial, but I would caution that it's retrospective data and randomized control trials are needed to confirm those benefits that we found. https://www.hcplive.com/view/off-label-tirzepatide-early-promise-type-1-diabetes-berry XX Looking ahead, though, a daily pill looks to be about as effective as a weekly Ozempic injection at inducing weight loss and lowering blood sugar. This is orforglipron. Like other GLP-1 medications, it mimics a hormone that regulates blood sugar and curbs appetite. Long way to go here for approval, but this and many other medications, are being raced to market to try to catch up with the established medications.. it’s thought one in 8 americans are now taking a GLP 1 https://www.nytimes.com/2025/06/21/well/new-weight-loss-drugs.html XX Sequel Med Tech has a launch date for its twiist system – coming up quick, July 7th. The twist uses Tidepool loop software Sequel announced in March that it agreed with Abbott to make the Libre system its first continuous glucose monitor (CGM) integration for twiist. The company also recently struck an agreement with Abbott to integrate with a future dual glucose-ketone sensor and has a deal to integrate the pump with the Senseonics Eversense 365 year-long implantable CGM. https://www.drugdeliverybusiness.com/sequel-launch-twiist-aid-system-july/ XX Medronic spins off ti’s diabetes business, which will now be called Minimed. At ADA they showed off their next tubed pump, the MiniMed 8-series, which is about half the size of its current 780G pump, has no screen and is controlled by a phone. Medtronic also showcased a patch pump in development. It has a semi-durable design with a rechargeable battery, a larger insulin reservoir, at 300 units, and a longer wear time, at seven days. No timeline for that, but likely not before 2027, Beta Bionics also showed a prototype for their new patch pump – they’re calling it Mint. This is also a mix of disposable and reusable components, last three days and take up to 200 units of insulin. You’ll hear from Tandem in our next episode, out this Tuesday.. they’re working on a tubeless option for its smaller Mobi insulin pumps and a separate patch pump called Sigi, which will be rechargeable and come with pre-filled insulin cartridges. The slim x3 is still also in the works. -- On the CGM front.. Abbot has signed deals for their future sensor that can detect glucose and ketones. They’re partnering with Tandem, Sequel and Beta Bionics so far. -- Dexcom is also working on monitoring ketones.. that will likely happen with the G8, now in trials. -- The Eversense CGM in the mix, showing off the plans they shared with us just a couple of weeks ago. Right now the Eversnese can stay on for a year.. next up is Gemini which is fully implantable – so no charging - but still needs a transmitter on top. Further out is Freedom, which would do away with the transmitter on top of the skin. https://www.medtechdive.com/news/ada-conference-diabetes-new-pumps-cgms/751482/ XX Once weekly basal insulin looks just as safe as daily basal in people with type 2. This is Lilly’s efsitora insulin.. Novo Nordisk, has received approval for use in adults with diabetes by the European Union and by Canada. Both companies hope to get approval in the US. https://www.medscape.com/viewarticle/once-weekly-efsitora-noninferior-daily-insulin-t2d-2025a1000gm1 XX XX Dexcom announces what it calls enhancements to event logging. You can add a photo to your meals and AI will populate meal descriptions. It won’t carb count, but it will identify the food. I’ve seen some demonstrations of this and it seems to work pretty well. You can log exercise as well and see how the food and activity will impact blood sugar. I can’t wait to ask Dexcom about this – I’ve got to believe their using all the data to work on a carb counting AI app here – where you’d just a take a photo and get the carb count OR you’d just take a photo and an AID system would know what to do.. that’s my speculation. XX An American Diabetes Association expert panel that Cusi helped lead recently published a consensus report that urges physicians to screen people with Type 2 diabetes or prediabetes for a liver disease triggered by accumulated fat in the organ. The condition — metabolic dysfunction-associated steatotic disease, or MASLD — often has no early symptoms but can progress to cirrhosis, liver failure and liver cancer without early diagnosis and intervention. The disorder, which can occur in those with or without diabetes, was previously known as nonalcoholic fatty liver disease. Liver screening is especially urgent, the report said, especially for those who have obesity and Type 2 diabetes. Some individuals with Type 1 diabetes who have obesity are also at risk. Early intervention, however, can reduce and even reverse the risk. Interventions include lifestyle and dietary changes, weight management and glucose-lowering medications. https://ufhealth.org/news/2025/new-report-recommends-liver-screening-for-those-with-type-2-diabetes XX XX Axiom Mission 4 (Ax-4), which lifted off from Kennedy Space Center in Florida this week. One of the mission’s most significant research initiatives, Suite Ride, is a , with the potential to transform the future of space travel for astronauts with insulin-dependent diabetes mellitus (IDDM), a condition historically considered disqualifying for space missions. The Suite Ride study will utilise Continuous Glucose Monitors (CGMs), which have become the standard for glucose monitoring in individuals with diabetes. These devices will be tested to ensure their accuracy in microgravity, providing real-time data that will ultimately support the health of astronauts with IDDM. The comprehensive preflight, inflight and postflight protocols will employ various testing methods to validate these technologies. The Ax-4 mission plans to look at insulin exposure in microgravity to assess the potency and stability of the drug product upon its return to Earth. https://gulfnews.com/uae/uae-led-diabetes-research-takes-off-to-space-on-axiom-mission-4-1.500176357
/episode/index/show/diabetesconnections/id/37165395
info_outline
Still Not Waiting: Lane Desborough's Bold New Push with Nudge
06/24/2025
Still Not Waiting: Lane Desborough's Bold New Push with Nudge
This week on Diabetes Connections, “We are not waiting” became more than just a slogan — it sparked a movement. Back when the diabetes community was fed up with slow progress, DIYers stepped in with solutions that actually worked better than what companies were offering. That rallying cry? It came from Lane Desborough in 2013. And more than a decade later, he’s still challenging the status quo. We’re catching up with Lane to talk about his latest project, Nudge — much more than just another insulin pump algorithm, it’s an innovation to create more open and accessible systems This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: info@diabetes-connections.
/episode/index/show/diabetesconnections/id/37112310
info_outline
Cloak the Poke: A New Way to Make Shots Less Scary
06/17/2025
Cloak the Poke: A New Way to Make Shots Less Scary
As we gear up for ADA Scientific Sessions and get ready to hear studies and reports from the big diabetes companies, I’ve decided to highlight something on the other end of the spectrum. College students, seeing a need and developing a solution. Cloak The Poke is all about addressing fear of needles, especially in kids. We’ll explain how it works, more about the team behind it, and their big goals going forward. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More about Join us at Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: info@diabetes-connections.
/episode/index/show/diabetesconnections/id/37025060
info_outline
In the News... Omnipod updates, Tandem + Abbott, Dr. Pepper Zero recall, American Ninja and more!
06/13/2025
In the News... Omnipod updates, Tandem + Abbott, Dr. Pepper Zero recall, American Ninja and more!
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: what is adaptive biobehavioral control for AID systems? Omnipod 5 launches iOS app with Dexcom G7 compatability and a comic book(?!), Tandem and Abbott announce new partnership, Katie Bone is back on American Ninja Warrior, and more! Find out more about Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX The American Diabetes Association Scientific Sessions kicks off in a week – we expect as always to get a lot of information! I’m not covering in person this year, but I’ll bring you any big announcements. And we’ll do a wrap up In the News the following week. -- XX UVA with something new.. technology that allows an artificial pancreas system to adapt to users’ changing needs – and lets users adjust the settings – beyond what’s commercially available now. They’re calling this “adaptive biobehavioral control,” the technology helps fine-tune UVA’s artificial pancreas every two weeks, giving users a virtual tool to test different ways to manage their blood sugar using their own data. In a six-month study, participants using the technology spent more time in a healthy blood-sugar range, rising from 72% to 77%, and saw a small but meaningful drop in their average blood-sugar levels. While automated insulin delivery systems help users better manage Type 1 diabetes, adaptive biobehavioral control technology is designed to improve blood-sugar control during the day, when fluctuations occur more frequently due to meals and physical activity. This new technology uses “digital twins,” computer models simulating how a person’s body processes sugar. The models help the artificial pancreas keep up with changes in the user’s body and habits and give users a way to interact with the system. For example, users can try different settings, like how much insulin is released overnight, using the simulation before applying them in real life. XX Five years later after COVID-19 his the US, a new study shows that there is a connection with type 1 diabetes triggers. This is new research from the University of Utah published in the journal ImmunoInformatics. With T1D in particular, a COVID infection appears to trigger the immune system of certain people who have a prior susceptibility to the condition to subsequently develop T1D symptoms, the new study suggests. University of Utah researchers hypothesize that COVID is leading to T1D diagnoses in a roundabout way as the virus presents the body with “molecular mimics,” or fragments of COVID proteins that bear an uncanny resemblance to those beta cell antigens. When a person is infected with COVID, the immune system not only attacks fragments of the viral protein but also attacks fragments of beta cell antigens because they look so similar and get mistaken for each other, explains lead study author Julio Facelli, Ph.D., a distinguished professor of biomedical informatics at University of Utah Health in Salt Lake City. That means that in people who are already predisposed to T1D, there may be a simultaneous autoimmune reaction involving the destruction of healthy beta cells, spurring the onset of type 1 diabetes. Both 2022 and 2024 research indicates that there has been a significant increase in new onset type 1 diabetes following the start of the COVID pandemic. It’s difficult to estimate just how many cases may have been triggered by COVID because numerous viruses, including rotavirus, measles, mumps, and rubella, can spark an autoimmune response that activates T1D, according to the 2022 research published in Immunology & Cell Biology. Again, it’s important to note that researchers don’t believe a COVID infection is causing diabetes, but rather, triggering it, in the same way certain environmental factors are believed to trigger immune-mediated conditions like Crohn’s and psoriasis. “ XX Insulet announces the Omnipod® 5 App for iPhone is now compatible with the Dexcom G7. Eric Benjamin, Insulet Executive Vice President, Chief Product and Customer Experience Officer. “With the addition of the Dexcom G7 sensor to the Omnipod 5 App for iPhone, our U.S. customers have more choice with fewer devices to keep track of, making it easier than ever to manage their diabetes.” The Omnipod 5 App with Dexcom G7 and Dexcom G6 compatibility is now available for download on the Apple App Store. Switching to a new Omnipod 5 device will require you to go through First Time Setup again. Insulin delivery history from previous Pods will be lost when you switch to your new device and adaptivity will start over. Use this guide and video to help transfer your settings: Omnipod also announced a collaboration with Marvel.. on an original comic to celebrate representation for the diabetes community and empower people with diabetes to unleash their inner hero. “Dyasonic: Sound of Strength” features Omnya, who was recently diagnosed with type 1 diabetes, struggles with her management, and is prescribed an insulin pump. Omnya learns that when her glucose levels are in range she can take on anything, and anyone, and transforms into the comic’s hero, Dyasonic! The hope is that readers will be able to see themselves overcoming these same challenges and break mental barriers to adopting technology with the potential for improved outcomes and quality of life. D’Spayre is a Marvel villain who preys on victims who are in despair, using their fear to strengthen himself—akin to the negative emotions that can come with diabetes. Insulet remains dedicated to advancing diabetes technology and improving the lives of people with diabetes. For more information, please visit . XX Tandem is the latest partner for Abbot’s future Glucose-Ketone Sensor. New agreement to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes. The Abbott sensor, currently under development, will combine glucose and ketone sensing technology that aims to help people living with diabetes detect early ketone rise to avoid life-threatening diabetic ketoacidosis. Sequel Med Tech is also partnering with Abbott on this, as part of the twist pump, launching later this year. XX New guidelines for the management of type 2 diabetes and prediabetes include tools clinicians can use to help patients stick to lifestyle interventions. A panel of practitioners working in lifestyle medicine, including primary care physicians, cardiologists, endocrinologists, sleep experts, dietitians, and exercise medicine specialists, laid out six areas clinicians should help patients manage. These include sleep and stress, nutrition, physical activity, tobacco and alcohol, and social connection. The guidelines, released on June 10 by the American College of Lifestyle Medicine (ACLM), largely mirror lifestyle guidelines by the American Diabetes Association (ADA) but add specifics about how clinicians can help patients achieve their goals. Each patient should still receive tailored counseling, which may include medication XX Microplastics from a widely used biodegradable material can enter the metabolic cycle of bacteria and cells in the gut after being ingested, a new study has found. Researchers in China and the United States said the microplastics – from polylactic acid – were found to alter the gut metabolism and damage the gut barrier of mice. They said this could potentially contribute to conditions like inflammatory bowel disease and diabetes. In recent years, microplastics have been found in human lungs, kidneys, blood, placenta and breast milk. XX Over 19,000 cases of Dr Pepper Zero Sugar are being recalled after the cans were found to contain full-sugar soda, the U.S. Food and Drug Administration announced. The voluntary recall, initiated May 23, affects 12-pack and 24-pack cases of the 12-ounce aluminum cans that are labeled “Dr Pepper Zero Sugar.” Despite the label, the drinks inside contain the same amount of sugar found in regular Dr Pepper — about 39 grams per can — posing a health risk for people with diabetes or anyone needing to limit sugar intake. On Thursday, June 5, the FDA officially classified the recall as Class II, meaning the product “may cause temporary or medically reversible adverse health consequences." DR PEPPER ZERO SUGAR - 12 OZ, 12 PK DR PEPPER ZERO SUGAR - 12 OZ, 12 PK. Amazon Consumers can identify the recalled cases by the product code, which is listed as XXXXRS05165, and the "best by" date of Feb. 16, 2026 No other Dr Pepper products or batches of Dr Pepper Zero Sugar are part of the recall. XX A step forward for a device that uses breath to gather information about blood sugar. It’s called Isaac, the company is PreEvnt, you wear it on a lanyard and breathe into it. The breathalyzer technology was developed in collaboration with the Integrated Nanosystems Development Institute at IU Indianapolis, and was inspired by diabetes alert dogs. "Our lab was able to successfully identify the specific molecules in breath that correlate with hypoglycemia, which is the 'scent' that diabetic alert dogs can detect," said Mangilal Agarwal, director of the Integrated Nanosystems Development Institute and a professor in the IU Luddy School of Informatics, Computing and Engineering at IU Indianapolis. Agarwal's lab is partnering with the IU School of Medicine to test and validate the effectiveness of the device in individuals with diabetes—an important next step on the path to wider commercialization. https://medicalxpress.com/news/2025-06-breathalyzer-device-diabetes.html#google_vignette XX Katie Bone is back on American Ninja Warrior! The youngest ever American Ninja Warrior Women’s National winner, she injured her knee at Olympic Climbing Trials in 2023. This week, she was back on the show. She says: Katie Bone: It was incredible. I’ve not been able to compete for a few years, so getting to come back and hit a buzzer on my first chance back on the course felt really, really incredible; Very rewarding after everything I had to go through to get back there. XX
/episode/index/show/diabetesconnections/id/36976285
info_outline
GLP-1 Medications for T1D: What your endo wants you to know
06/10/2025
GLP-1 Medications for T1D: What your endo wants you to know
More and more people with type 1 are using GLP-1 receptor agonists. You know these medications, with brand names like Ozempic, Mounjaro, Wegovy and Zepbound, but none of them are specifically approved to treat T1D. Some of the first studies are underway to study the safety and effectiveness of GLP-1s, but that hasn’t stopped thousands of using them off-label or to treat obesity. We’re talking to an endocrinologist and a clinical pharmacist about why they prescribe these meds to some of their type 1 patients, who they won’t prescribe them for, and – I know you’re already asking – how they get insurance coverage. My guests are endocrinologist Dr. Adam Spitz and Clinical Pharmacist Georgina Farrow This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: info@diabetes-connections.
/episode/index/show/diabetesconnections/id/36905820
info_outline
Why Diabetes Camp Matters More Than Ever: A Conversation with DECA’s Lisa Gier
06/05/2025
Why Diabetes Camp Matters More Than Ever: A Conversation with DECA’s Lisa Gier
It’s time to talk about summer camp! Kids may be getting ready to go, already there, or maybe you’re an adult with type 1 who has fond memories or is working at camp. We’re talking to the which serves the diabetes camp community. Lisa Gier is the executive direction of DECA – she lives with type 1, attended camp and her son who also has T1D now goes to the camp she attended as a child. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: info@diabetes-connections.
/episode/index/show/diabetesconnections/id/36861445
info_outline
Tubeless, smarter & interoperable: A look into Medtronic’s future plans
05/27/2025
Tubeless, smarter & interoperable: A look into Medtronic’s future plans
A conversation with a Medtronic engineer who’s been with the company since the beginning of the Artificial Pancreas project. Lou Lintereur is now Chief Engineer for AID systems at Medtronic.. we talk about the recently approved Simplera Sync Sensor, changes coming to Medtronic pumps, he answers your questions about AI use, patch pumps, and the idea of a pump that needs zero user interaction. Note: this episode was recorded before Medtronic's announcement that they will spin off the Diabetes division. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: info@diabetes-connections.
/episode/index/show/diabetesconnections/id/36648795
info_outline
"The Worst Game Ever" - Sam Glassenberg wants to change how we learn about T1D
05/20/2025
"The Worst Game Ever" - Sam Glassenberg wants to change how we learn about T1D
Learning through video games isn’t new – there are games aimed at almost every profession, even healthcare. Sam Glassenberg is the founder of Level Ex which makes those types of learning games – and when his daughter was diagnosed with type 1.. he was appalled at the on-boarding process which he called the worst game ever, full of frustration and punishment for the patient and caregiver. So Sam developed Level One – a new free game to teach type 1. We’re talking about how it works, who it’s for, and what makes it different from those gamification flops you may remember from years ago. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: info@diabetes-connections.
/episode/index/show/diabetesconnections/id/36612430
info_outline
In the News...Tandem's new infusion set approved, Sernova cell-pouch moves forward, GLP-1 meds for T1D, and more!
05/16/2025
In the News...Tandem's new infusion set approved, Sernova cell-pouch moves forward, GLP-1 meds for T1D, and more!
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Tandem's new infusion set is approved, Dexcom G7 compatibility with the Omnipod 5 iPhone app announced, Sernova cell-pouch moves forward, GLP-1 meds for T1D, and more! Find out more about Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Tandem gets FDA clearance for a new infusion set. The company shared in an SEC filing that its Capillary Biomedical (CapBio) subsidiary won clearance for its SteadiSet Infusion Set. SteadiSet features an integrated inserter with a hidden needle designed for one-handed insertion. It received clearance to deliver insulin for up to three days of use. However, Tandem plans to submit a separate request to extend the indicated use time to up to seven days. It doesn’t expect to begin commercial activities for SteadiSet until after it receives clearance for the extended use time. Many of us have been following this since Tandem acquired CapBio back in 2022.. it’s been pretty hush hush – CapBio has never accepted my requests for interviews, so I’m excited to see this approval, mostly because my son really really needs it! https://www.drugdeliverybusiness.com/tandem-capbio-fda-clearance-insulin-infusion-set/ XX Insulet just announced via an email to health care providers that Dexcom G7 compatibility with the Omnipod 5 iPhone app will be released IN THE COMING WEEKS! Great news for people with and XX Sernova announces positive interim data from its ongoing Phase 1/2 clinical trial in patients with T1D. this is their Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today Interim data from 12 patients with transplanted human donor islet cells show patients achieving insulin independence, islet cell engraftment in Cell Pouch, islet function, islet survival, improved glycemic control, improved patient reported quality of life (QOL) and improved awareness of hypoglycemia and increased sensitivity to severe hypoglycemic symptoms. Improvement in patient outcomes was correlated with a cumulative increase in the quantity of transplanted islets. Based on these findings, the study is on track to meet its primary and secondary endpoints, and the confirmatory Cohort C is expected to initiate in H2 2025. Clinical trials with iPSC islet-like clusters from Sernova’s partner, Evotec, are anticipated to begin in 2026 after completion of Cohort C of the ongoing trial. These interim findings, with 8 of 12 patients achieving insulin independence so far, support the thesis that Sernova’s high volume ten channel Cell Pouch, used in Cohort B, plus an optimised immune suppression regimen, has the potential to achieve insulin independence, without portal vein transplant, in our planned clinical trial with Evotec’s high quality iPSC islet-like clusters. Measured HbA1c (a blood test that shows the average blood sugar levels over the past 2-3 months) in patients with Cell Pouch alone, showed that 9 of 12 patients had a reduced value within the American Diabetes Association (ADA) recommended range of <7.0%. Of the remaining 3 patients, 1 experienced a 24% reduction in HbA1c from 10.3% to 7.8% and the other 2 maintained a normal HbA1c value of <7% as measured at baseline. Published clinical studies found that each 1% reduction in A1c was associated with a 14 % reduced risk of myocardial infarction. A single portal vein transplant resulted in all Patients having a recommended HbA1c of <7.0% that was maintained for the duration of the study. https://sernova.com/press_releases/sernova-biotherapeutics-provides-positive-interim-data-from-ongoing-phase-1-2-clinical-trial-of-cell-pouch-bio-hybrid-organ-in-patients-living-with-type-1-diabetes/ XX A new study in the European Heart Journal shows that people who develop type 1 diabetes in adulthood have an increased risk of cardiovascular disease and death, and that those diagnosed later in life do not have a better prognosis than those diagnosed earlier. But the study points to smoking, poor glucose control and obesity as the main risk factors. The registry-based study identified 10,184 people diagnosed with type 1 diabetes in adulthood between 2001 and 2020 and compared them to 509,172 matched people in the control group. The study shows that these people with adult-onset type 1 diabetes had a higher risk of cardiovascular disease and death from all causes, including cancer and infections, compared to the control group. "The main reasons for the poor prognosis are smoking, overweight/obesity and poor glucose control. We found that they were less likely to use assistive devices, such as insulin pumps," "But we show that the prognosis can be significantly improved by preventing smoking and obesity and improving glucose control, not least in people diagnosed at older ages," explains senior author Sofia Carlsson, senior lecturer and associate professor at the same department. The researchers plan to continue investigating adult-onset type 1 diabetes, including risk factors for developing the disease and the prognosis of other outcomes, such as microvascular complications. Optimal treatment in adult-onset type 1 diabetes, including the effect of pump use and other advanced technologies, also needs to be explored. XX Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, today announced the publication of two peer-reviewed journal articles that expand insight into the burdens of living with T1D in 2025. The papers shine a much-needed light on the burdens facing people who live with this lifelong, demanding disease that causes the pancreas to make very little insulin or none at all, and the immediate need to accelerate life-saving cures for T1D through cell therapy. Authored by a team of Breakthrough T1D executives, including CEO Aaron J. Kowalski, PhD, "The Urgent Need for Breakthrough Therapies and a World Without Type 1 Diabetes", published in Diabetes Therapy, challenges the misperception that insulin therapy and today's diabetes technologies are meeting the needs of people with T1D. The paper stresses that although progress has been made in managing T1D, the disease still results in premature death, significant complications and a substantial daily burden for those affected by it. It argues that accelerating cell therapies which restore the body's ability to produce its own insulin are key to T1D cures. The Breakthrough T1D authors emphasize the need for the entire T1D community, including researchers, regulators, policymakers, and people living with T1D to work together to hasten the development of novel T1D therapies. The second paper, "We Are on the Verge of Breakthrough Cures for Type 1 Diabetes, but Who Are the 2 Million Americans Who Have It?", published in the Journal of Health Economics and Outcomes Research, shares valuable demographic information on the broad spectrum of Americans living with T1D and predicts the changes this population will undergo in the next decade. Once viewed as a condition that could only be diagnosed in childhood, it is now known that T1D can develop at any age. XX Experts are also interested in other uses of semaglutide. A recent study published in The New England Journal of Medicine furthered research on semaglutide, exploring how the drug affected outcomes for people with metabolic dysfunction-associated steatohepatitis, a type of liver disease. The results suggest that semaglutide may help resolve steatohepatitis and decrease fibrosis. Semaglutide improves liver outcomes This research was a phase 3 clinical trial involving people with metabolic dysfunction-associated steatohepatitis (MASH). As described in this study, MASH is a severe type of what used to be called nonalcoholic fatty liver disease. The study also notes that MASH involves damage to liver cells, inflammation, and steatosis or fat buildup in the liver. Steatohepatitis, which involves fat buildup and inflammation in the liver, can then contribute to tissue scarring or fibrosis. This study involved participants from hundreds of clinical sites in thirty-seven countries. The current published results report the end of the first part of the trial. XX For the first time, researchers are exploring the effectiveness of tirzepatide – which is currently only approved for type 2 diabetes – for people with type 1 diabetes and obesity or overweight. Trial status: Recruiting Clinical Trials Identifier: NCT06914895 Trial Name: A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight (SURPASS-T1D-1) Diabetes Type: Type 1 diabetes Trial Sponsor: Eli Lilly Why is this study important? GLP-1 medications have traditionally been off-limits for people with type 1 diabetes due to concerns around risks like hypoglycemia and diabetic ketoacidosis (DKA). That may change with a new study – the first-of-its-kind – testing tirzepatide in people with type 1 diabetes and obesity or overweight. Tirzepatide is a GLP-1/GIP therapy currently FDA-approved for weight management (Zepbound), type 2 diabetes (Mounjaro), and sleep apnea. Research indicates the same benefits drugs like tirzepatide have for type 2 diabetes – improved blood sugar levels, increased time in range, and proven benefits for both the heart and kidneys – would likely extend to people with type 1. This study represents a first step towards a monumental win for the type 1 community. If successful, tirzepatide could become the first GLP-1/GIP therapy approved for type 1 diabetes. How does the trial work? Participants will be randomly assigned to one of four tirzepatide dosing groups or the placebo group. Those assigned to a treatment group will receive a once-weekly subcutaneous injection of tirzepatide while the other group will receive a weekly placebo injection. The study will last about 49 weeks and may include up to 23 visits. To determine the safety and effectiveness of tirzepatide, researchers will measure changes in A1C, time in range, body weight, blood pressure, and cholesterol. Are you interested in participating? You may be eligible to participate if you are 18 years or older and have: Type 1 diabetes and have been on insulin for at least one year prior to screening An A1C of 7% to 10.5% at screening A body mass index of 25 or higher at screening Stable weight for at least 90 days prior to screening and agree not to start an intensive diet or exercise program during the study People who have had two or more hospitalizations for hyperglycemia or DKA in the past six months, have had one or more emergency treatments for severe hypoglycemia in the past three months, or are receiving treatment for diabetic retinopathy or macular edema are not eligible to participate in this study. See a full list of inclusion/exclusion criteria here. This trial is currently recruiting in multiple locations worldwide. To enroll or learn more about this study, contact [email protected] or call 1-877-285-4559. XX Roche Diagnostics will build a $550 million expansion to produce continuous glucose monitors at an Indianapolis facility. Roche will use the site to make its Accu-Chek Smartguide devices, which launched last year in Europe as the company’s first CGM. The Indianapolis site is Roche Diagnostics’ North American headquarters. It houses research and development, laboratories, manufacturing and other functions, and produces Roche’s Accu-Chek diabetes test strips. The facility is one of two global distribution hubs for the company. Roche received a CE Mark in July for its Accu-Chek Smartguide CGM. The device, which can be worn for 14 days, incorporates predictive algorithms to estimate users’ glucose levels over two hours and nocturnal hypoglycemia risk. However, users must calibrate the CGM using a finger stick, which some newer devices from Abbott and Dexcom don’t require. https://www.medtechdive.com/news/roche-manufacturing-indiana-cgm/747809/ XX Excited to see Go Pen receive FDA approval- an inspiring journey from wining our innagrial Innovation Challenge to helping people with diabetes . They solve the challenge faced by the 13 million people worldwide living with diabetes who don’t have access to insulin pens for their daily injections. Instead, they use a disposable syringes with all the inherent inaccuracies A low cost global option to convert vial to reusable insulin pen use Inspired leadership from the caring and team. This is how can meet unmet needs of people with XX https://www.liebertpub.com/doi/10.1089/dia.2025.0169 XX Ascensia announces that Eversense 365 has been named the Best New Technology Solution for Diabetes Management in the 2025 annual MedTech Breakthrough Awards Program. This follows a Gold award at the Edison Best New Products Awards, where Eversense beat Abbot’s Lingo CGM. Eversense 365 is the only long-term CGM system available, offering people with diabetes a truly differentiated CGM experience, providing one year of exceptionally accurate monitoring with minimal interruptions. The tiny implantable sensor and unique approach to CGM also allows people to overcome common frustrations and interruptions experienced with traditional short-term CGMs, so they can focus on managing their diabetes and not their device. Eversense 365 is currently available in the US and indicated for people with diabetes 18 years and older; an application for European CE Mark registration has been filed to allow Eversense 365 to be marketed in Europe. Eversense 365 has also recently partnered with Sequel Med Tech to create the first automated insulin delivery system with a one-year CGM. The integrated system is expected to launch in Q3 of 2025. XX Front office change at Dexcom.. Jake Leach, who joined Dexcom in 2004 to lead the development of sensor electronics for its first commercial CGM system, now has a new title. Leach, who became the company's COO in 2022, is now president and COO at the San Diego-based company. As COO, he provides end-to-end responsibility for product development and oversight of executive leadership , as president on top of that, he takes on the additional responsibility of overseeing corporate development and strategy efforts at Dexcom. Full story here: XX
/episode/index/show/diabetesconnections/id/36583230
info_outline
Eversense 365 + twiist: exploring the newest CGM/pump combo
05/13/2025
Eversense 365 + twiist: exploring the newest CGM/pump combo
This week on Diabetes Connections, the Eversense CGM gets its first pump partner. This is the implantable CGM sensor – it now lasts for a year.. and it will soon connect with the twist.. a brand new insulin pump. I’m joined by Brian Hansen, the president of CGM at Ascenia, that’s the company that distributes Eversense, to talk about how this will work, what’s changed for eversense, besides the much longer wear, and what the future holds. This was a wide ranging conversation and a fun one. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. My guest Brian Hansen was appointed the this president of CGM in early 2024. Before that, among other jobs, he chief commercial office at Tandem. We have followed Eversense for a long time, including talking to people who have worn it for a long time – I’ll link up our previous episodes in the show notes. Our previous Join us at Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: info@diabetes-connections.
/episode/index/show/diabetesconnections/id/36522985
info_outline
Dexcom Stelo + Oura Ring: all about the new “Glucose” feature (Bonus episode!)
05/07/2025
Dexcom Stelo + Oura Ring: all about the new “Glucose” feature (Bonus episode!)
Dexom and Oura announced a partnership a few months ago and now they've announced a new integration. This is the Dexcom Stelo – the OTC biosensor (they don’t call it a CGM) for people who don’t use insulin and Oura a smart ring for fitness stress sleep and health. This first to market glucose biosensor and smart ring integration will provide members with a personalized metabolic health experience that will allow users to better understand the link between activity, sleep, stress, nutrition and their glucose. It will be available in the new Glucose feature within the Oura Ring app to all US members. Also, Dexcom and Oura are making this partnership as accessible as possible by allowing Oura members to purchase Stelo directly from ouraring.com. My guest is endocrinologist Dr. Helen Baron, Medical Director of Diabetes Education Services at Eisenhower medical center in California. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: info@diabetes-connections.
/episode/index/show/diabetesconnections/id/36454160
info_outline
T1D help in real-time: StrideMD offers 24/7 remote monitoring
05/06/2025
T1D help in real-time: StrideMD offers 24/7 remote monitoring
Remember that ad : I’ve fallen and I can’t get up? do we need a life alert for type 1 diabetes? I’m talking to the folks behind StrideMD – a Florida based healthcare company that is using remote monitoring to alert their clients, and event notify emergency contacts and paramedics if needed. How does it work, who is it for, and would you consider it? My guest this week is Stride MD Chief Operating Officer Scott Hozebin. Their based in Florida and right now are only in operation there.. but hope to expand. And they’re an official partner with Dexcom. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: info@diabetes-connections.
/episode/index/show/diabetesconnections/id/36436450
info_outline
In the News... New drug tested to prevent type 1, twiist pump integrates with Eversense CGM, Dexcom U is back, and more!
05/02/2025
In the News... New drug tested to prevent type 1, twiist pump integrates with Eversense CGM, Dexcom U is back, and more!
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: A new Austrailian study aims to prevent type 1, the new twiist pump will integrate with Eversnse CGM as well as Libre, diabetes deaths are down in the US, Dexcom U is looking for college athletes, and more! Find out more about Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX A world-first human trial of a drug designed to treat the underlying cause of type 1 diabetes has begun in Australia. University of Queensland researcher Ranjeny Thomas said the experimental drug — dubbed ASITI-201 — was designed to retrain the immune system so it no longer attacks the insulin-producing pancreatic cells, known as beta cells. The drug, given as an injection under the skin, combines fragments of a protein found in the beta cells of people with type 1 diabetes and vitamin D to calm the immune response. She said if effective, the drug would initially be given to patients with type 1 diabetes as soon as possible after diagnosis to preserve remaining pancreatic cells and reduce the amount of insulin needed. But eventually, if screening programs can be developed to pick up people at risk of developing type 1 diabetes, it may be possible to "prevent the progression of the disease altogether". The first in-human trial of 36 participants will test the safety of the drug, but blood tests will also determine the impact of the therapy on a patient's immune system and glucose tolerance. https://www.abc.net.au/news/2025-04-29/type-1-diabetes-drug-trial-auto-immune-disease-science/105223022 XX Diabetes deaths in the U.S. have fallen to some of the lowest rates in years, according to new preliminary figures published by the Centers for Disease Control and Prevention, reversing a surge in mortality that was seen during the COVID-19 pandemic. There were 26.4 deaths per 100,000 people from diabetes, according to early death certificate data for the third quarter of 2024 published this month by the CDC's National Center for Health Statistics. Death rates from diabetes peaked in 2021, according to CDC figures, at 31.1 deaths per 100,000 people for that year. Diabetes was the eighth leading cause of death in 2021. The CDC says the link between COVID-19 and diabetes may be to blame for that increase. "Data show an increase in mortality rates for all people during the COVID-19 pandemic, and research shows that people with underlying conditions, including diabetes, are more likely to become very sick from COVID-19 and have a higher risk of hospitalization and death," Christopher Holliday, head of the CDC's Division of Diabetes Translation, told CBS News in a statement. Holliday added that research shows the pandemic may also have made it harder for Americans to properly manage the disease, ranging from interruptions to physical activity to disruptions to routine medical care diagnosing and treating the disease. https://www.cbsnews.com/news/diabetes-deaths-lowest-levels-years-early-cdc-figures/ XX Big news for the Eversense CGM – they have their first pump partner. Sequel Med Tech says the twist pump will integrate with Senseonics Eversense 365 continuous glucose monitor (CGM). This collaboration would make twiist the first AID system compatible with Eversense 365, the world’s first and only one-year CGM. Sequel and Senseonics say they have already started their work to integrate the latest-generation, 365-day implantable sensor with twiist. They expect to make the integrated offering available in the third quarter of this year. This marks the second CGM integration for Sequel, which earlier this year. This week we also got a peek at the packaging and delivery of the twist as the first people posted about wearing it. We’ll follow up and learn more about this newest insulin pump in the us. Senseonics, meanwhile, brought the first year-long CGM to market last year, launching . The system also received clearance as an integrated CGM (iCGM) system, meaning it can work with compatible medical devices. Those include insulin pumps as part of automated insulin delivery systems. XX Medtronic has announced the U.S. Food and Drug Administration (FDA) approval for the Simplera Sync sensor for use with the MiniMed 780G system. With this approval, the MiniMed 780G system now offers more flexibility for users of the company’s most advanced insulin delivery system featuring Meal Detection technology with both the Guardian 4 sensor and Simplera Sync sensor. The Simplera Sync is a disposable, all-in-one sensor that requires no fingersticks with SmartGuard or overtape and features a simple, two-step insertion process. It is the company’s newest addition to its CGM portfolio, which expands options and provides greater flexibility for users. The MiniMed 780G system’s adaptive algorithm automatically anticipates, adjusts, and corrects glucose levels every 5 minutes, 24/7 – working around the clock so users can focus on what matters. It’s the only system featuring Meal Detection technology, which detects rising sugar levels and delivers more insulin as needed to help users keep glucose levels in range more often – even when users occasionally forget to dose insulin for snacks or meals or underestimate their carbs. The system uses a “treat to target” approach and flexible glucose targets as low as 100 mg/dL, which, combined with its adaptive algorithm allows it to more closely mirror the glucose levels of someone not living with diabetes. Real-world data of the system shows global users consistently achieve time in range above international targets of 70% when using optimal settings (active insulin time of two hours and 100 mg/dL target glucose). It is also the only system that works with the world’s only infusion set that lasts up to 7 days so that users only have to change their infusion set once per week and can experience 96% fewer injections compared to multiple daily injections. “We’re committed to driving innovation that makes life easier for those living with diabetes so they can forget about their diabetes as much as possible throughout the day,” said Que Dallara, EVP and president of Medtronic Diabetes. “Our MiniMed 780G system delivers advanced diabetes technology for so many around the world, and we’re excited to continue evolving this experience with expanded CGM options —including our Simplera Sync sensor, which we look forward to bringing to people living with diabetes in the U.S.” A limited launch of the Simplera Sync sensor will begin in the U.S. in the fall of 2025. Today, the MiniMed 780G system can be used with the Guardian 4 sensor. Like this:https://med-techinsights.com/2025/04/29/simplera-sync-sensor-for-minimed-780g-now-fda-approved/ XX Front office changes at Insulet.. The former head of Johnson & Johnson’s worldwide medtech business, Ashley McEvoy will take over as president and CEO from Jim Hollingshead, who has led Insulet since 2022. In its announcement of the leadership change, Insulet said that Hollingshead and the company mutually agreed to part ways, effective immediately. McEvoy served as worldwide medtech chairman at J&J from 2018 until her departure in late 2023, the culmination of nearly 30 years at the company and several executive roles—including president of its Ethicon division and group chairman of vision and diabetes care. Since then, she has also served as a board member at Procter & Gamble. https://www.fiercebiotech.com/medtech/insulet-taps-former-jj-medtech-head-ashley-mcevoy-be-ceo XX New free mobile game launched this week to make type 1 diabetes onboarding faster easier and less overwhelming. It’s called Level One.. created by Level Ex (Powered by Relevate Health), the studio behind award-winning medical games for medical professionals. Level Ex CEO Sam Glassenberg created the game after a – quote - brutal onboarding experience when his daughter was diagnosed five years ago He says It took a year to understand how to manage this disease. So we fixed it. We built a game that can train your brain to do it in a matter of hours." The game is launching in partnership with leading diabetes organizations Beyond Type 1 and Breakthrough T1D Play, who are integrating Level One into their outreach and educational campaigns to support newly diagnosed families worldwide. Download Level One on the App Store: https://apps.apple.com/us/app/level-one-a-diabetes-game/id6739605694 Learn more: https://playlevelone.com XX Collagen is widely recognized for its role in maintaining healthy skin, but its importance extends far beyond that. As the most abundant protein in the human body, collagen provides essential structure and support to nearly all tissues and organs. Now, researchers at Carnegie Mellon’s Feinberg Lab have made a major breakthrough using their novel Freeform Reversible Embedding of Suspended Hydrogels (FRESH) 3D bioprinting technique. This method enables the precise printing of soft, living cells and tissues. Leveraging this technology, the team successfully created the first-ever microphysiologic system, also known as a tissue model, constructed entirely from collagen. This advancement opens new possibilities for studying disease and engineering tissue therapies, including potential treatments for conditions like Type 1 diabetes. Traditionally, small-scale models of human tissue, referred to as microfluidics, organ-on-chip devices, or microphysiologic systems, have been fabricated using synthetic materials such as silicone rubber or plastics. These materials were necessary due to limitations in earlier manufacturing techniques. However, because they are not biologically native, they fail to fully replicate natural tissue environments, restricting their effectiveness in biomedical research and therapeutic development. “Now, we can build microfluidic systems in the Petri dish entirely out of collagen, cells, and other proteins, with unprecedented structural resolution and fidelity,” explained Adam Feinberg, a professor of biomedical engineering and materials science & engineering at Carnegie Mellon University. “Most importantly, these models are fully biologic, which means cells function better.” Building Complex Tissues with FRESH Bioprinting In new research published in Science Advances, the group demonstrates the use of this FRESH bioprinting advancement, building more complex vascularized tissues out of fully biologic materials, to create a pancreatic-like tissue that could potentially be used in the future to treat Type 1 diabetes. This advancement in FRESH bioprinting builds on the team’s earlier work published in Science, by improving the resolution and quality to create fluidic channels that are like blood vessels down to about 100-micron diameter. “There were several key technical developments to the FRESH printing technology that enabled this work,” described Daniel Shiwarski, assistant professor of bioengineering at the University of Pittsburgh and prior postdoctoral fellow in the Feinberg lab. “By implementing a single-step bioprinting fabrication process, we manufactured collagen-based perfusable CHIPS in a wide range of designs that exceed the resolution and printed fidelity of any other known bioprinting approach to date. Further, when combined with multi-material 3D bioprinting of ECM proteins, growth factors, and cell-laden bioinks and integration into a custom bioreactor platform, we were able to create a centimeter-scale pancreatic-like tissue construct capable of producing glucose-stimulated insulin release exceeding current organoid based approaches.” https://scitechdaily.com/scientists-bioprint-living-tissues-that-could-revolutionize-diabetes-treatment/ XX Another study showing the blood sugar benefit of walking after a meal. Skeletal muscle plays a central role in glucose uptake. Exercise stimulates glucose transport into muscle cells through insulin-independent pathways, notably through the action of glucose transporter type 4 (GLUT-4), which is responsible for transporting glucose from blood to skeletal muscles.4 This means that even without a robust insulin response, physical activity can facilitate glucose clearance from the bloodstream. These effects also occur without requiring high-intensity exercise, making postprandial walking accessible to a broad range of individuals, including those with limited exercise tolerance. multiple studies show that starting activity within 30 minutes after a meal is optimal. XX Dexcom brings back Dexcom U for a 4th years. This is a name, image and license program for college athletes with diabetes and includes a nationwide open call for passionate and inspiring college athletes to join its roster. Now through May 23, athletes, coaches, friends and family members can nominate candidates through an online submission. Those selected, along with the eight returning athletes from last year, will be invited to attend the Dexcom U Signing Day Camp this summer, hosted by Dexcom Warrior and Baltimore Ravens tight end Mark Andrews. https://www.hmenews.com/article/dexcom-u-returns-for-fourth-season
/episode/index/show/diabetesconnections/id/36397175
info_outline
The Overlooked Challenges of Women with type 1 diabetes, with Courtney Pickett
04/29/2025
The Overlooked Challenges of Women with type 1 diabetes, with Courtney Pickett
Research is finally focusing on women with type 1 – hormones, periods, menopause. But there’s not a lot of guidance or conclusions yet. So what can you do to feel good now? I’m talking to Courtney Pickett this week – she lives with type 1, was a labor and delivery nurse, and is the founder of The CP Table, a holistic health coaching company. We’ll get her takes on everything from food, to frustration of cyclical blood sugar fluctuations, the pressure to be perfect and more. As Courtney says, women’s bodies are bad ass! This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More about Join us at Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: info@diabetes-connections.
/episode/index/show/diabetesconnections/id/36338345
info_outline
G7 15-Day Approval: Dexcom’s Jake Leach Answers Your Questions
04/22/2025
G7 15-Day Approval: Dexcom’s Jake Leach Answers Your Questions
Dexcom G7 gets FDA approval for 15-day wear. It’s in adults-only and should hit the market in the second half of this year. I’m talking to Chief Operating Officer Jake Leach about this newest advance for Dexcom, why they didn’t go for pediatric approval, their partnership with sleep ring company Oura, what else is coming this year from Dexcom and I’m asking a lot of your questions. Read the This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: info@diabetes-connections.
/episode/index/show/diabetesconnections/id/36243310
info_outline
In the News.. GLP-1 for T1D trials, Ozempic pill, Dexcom 15-day sensor, type 5 diabetes, and more!
04/18/2025
In the News.. GLP-1 for T1D trials, Ozempic pill, Dexcom 15-day sensor, type 5 diabetes, and more!
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Eli Lilly will start a lcinical trial for tirzepatide for people with type 1 diabetes, more details on Dexcom's 15 day G7 sensor, Ozepmic pill form tested, type 5 diabetes identified and more! Find out more about Please visit our Sponsors & Partners - they help make the show possible! Learn more about from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Here's where to find us: Learn more about everything at our home page Reach out with questions or comments: Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Our top story this week.. Eli Lilly takes the first steps toward getting tirzepatide approved for people with type 1 diabetes. Tirzepatide is sold under the brand names Mounjaro for type 2 and Zepbound for obesity. The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or are overweight. Participation in the study will last about 49 weeks. Official Title A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Tirzepatide Once Weekly Compared to Placebo in Adult Participants With Type 1 Diabetes and Obesity or Overweight This is a big deal because, even though many people with type 1 are able to get a prescription for tirzepatide, it’s not approved for T1D and so insurers won’t usually cover it. XX The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on the drugs’ safety and effectiveness for the condition. The family of medications called GLP-1 receptor agonists includes drugs like Wegovy, Zepbound, Ozempic, Mounjaro and Victoza. But the clinical trials of these medications specifically excluded people with type 1 diabetes, who are dependent on the hormone insulin to survive because they can’t make enough of their own. Drugmakers feared that using the GLP-1 medications with insulin might raise the chance of dangerously low blood sugar events, or hypoglycemia, and were unwilling to take the risk of studying them in people with type 1. For the study, which was published last month in the journal Diabetes, Obesity, and Metabolism, researchers at Johns Hopkins University reviewed the medical records of more than 200,000 people with type 1 diabetes from 2008 to 2023. They grouped the data in three-year periods, starting with October 2008 to September 2011 and ending with October 2020 to September 2023. GLP-1 medication use spiked, as well. Among adults with the highest category of obesity, about 4% used GLP-1 medications in 2008, and 33% did by 2023 – an 800% increase. But these are anecdotal reports and may not reflect instances in which people have side effects or complications like low blood sugar, which can be life-threatening. But Shin says what’s really needed is information from randomized, double-blinded studies, in which participants are followed forward in time and given either a drug or a placebo. https://www.cnn.com/2025/04/09/health/glp-1-type-1-diabetes-study/index.html XX Later this month the FDA will conduct a final meeting regarding a new, investigational compound (sotagliflozin) soda-GLIFF-a-zin that has been shown to Improve QoL and Reduce Long-term Complications for people with type 1 diabetes (T1D). The patient advocacy group Taking Control of Your Diabetes (TCOYD.org) is working to inform the T1D community about sotagliflozin - and to encourage people to sign a Change.org petition directed towards FDA. Last fall, the FDA declined to approve sotagliflozin due to concerns about a potential increased risk of diabetic ketoacidosis (DKA), despite this being a condition that people with T1D on insulin face and manage daily. While TCOYD respects FDA’s caution, the group stands by T1D patients and their physicians who, as a team, balance risks and benefits every day. XX Dexcom receives FDA approval for it’s G7 with 15 day wear. We have an interview with Chief Operating Officer Jake Leach coming up on Tuesday – we talk about the planned roll out of this sensor, what else has changed, and the fine print in the press release – it says “A study was conducted to assess the sensor life where 73.9% of sensors lasted the full 15 days. When using the product per package labeling, approximately 26% of sensors may not last for the full 15 days. https://investors.dexcom.com/news/news-details/2025/Dexcom-G7-15-Day-Receives-FDA-Clearance-the-Longest-Lasting-Wearable-and-Most-Accurate-CGM-System/default.aspx?utm_source=www.diabetech.info&utm_medium=referral&utm_campaign=dexcom-g7-15-day-sensor-gets-fda-cleared-but-will-it-actually-last-that-long XX Glucotrack is joining something called FORGETDIABETES bionic pancreas initiative, - this is an European Union project that aims to develop a long-term automated insulin delivery system for type 1 diabetes patients. Glucotrack's Continuous Blood Glucose Monitor (CBGM) will be integrated into the system to provide real-time glucose readings. The initiative's goal is to create a bionic invisible pancreas that eliminates the need for therapeutic actions and reduces psychological burden. The architecture of BIP encompasses a ground-breaking, lifelong lasting implanted ip glucose nanosensor; a radically novel ip hormone delivery pump, with unique non-invasive hormone refill with a magnetic docking pill and non-invasive wireless battery recharge; an intelligent closed-loop hormone dosing algorithm, optimized for ip sensing and delivery, individualized, adaptive and equipped with advanced self-diagnostic algorithms. Pump refilling through a weekly oral recyclable drug pill will free T1D subjects from the burden of pain and awkward daily measurement and treatment actions. Wireless power transfer and data transmission to cloud-based data management system round-up to a revolutionary treatment device for this incurable chronic disease. key feature of BIP is to be fully-implantable and life-long lasting thanks to novel biocompatible and immune-optimized coatings guaranteeing long-term safety and stability https://www.stocktitan.net/news/GCTK/glucotrack-to-participate-in-forgetdiabetes-a-prominent-european-cjjldjb0dq7h.html XX A newly recognised form of diabetes, called Type 5, was announced this week at the World Congress of Diabetes 2025. A global task force will investigate this less-understood condition, which differs from Type 1 and Type 2 diabetes. Type 5 diabetes affects people who are underweight, lack a family history of diabetes and do not show the typical symptoms of Type 1 or Type 2 diabetes. The condition was first observed in the 1960s and referred to as J-type diabetes, after being detected in Jamaica. It was classified by the World Health Organisation in 1985, but removed in 1998 due to lack of physiological evidence. At the time, experts believed it to be a misdiagnosed case of Type 1 or 2 diabetes. New research has since confirmed that Type 5 is different. https://economictimes.indiatimes.com/news/new-updates/a-new-type-of-diabetes-has-been-found-by-scientists-and-it-doesnt-show-the-typical-symptoms-of-type-1-or-type-2/articleshow/120276658.cms?from=mdr XX Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. A new clinical trial, co-led by endocrinologist and diabetes specialist John Buse, MD, PhD, and interventional cardiologist Matthew Cavender, MD, MPH, at the UNC School of Medicine, has demonstrated that the oral form of semaglutide significantly lowers the risk of cardiovascular events in individuals with type 2 diabetes, atherosclerotic cardiovascular disease, and/or chronic kidney disease. Results from the rather large, international trial were published in the New England Journal of Medicine and presented at the American College of Cardiology’s Annual Scientific Session & Expo in Chicago, Illinois. The effect of oral semaglutide on cardiovascular outcomes was consistent with other clinical trials involving injectable semaglutide, but more trials are needed to determine if one method may be more effective than the other at reducing major cardiovascular events. https://scitechdaily.com/new-pill-form-of-semaglutide-shows-major-benefits-for-people-with-diabetes/ XX April 14 (UPI) -- The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to treat Type 2 diabetes, have been found in the United States. Novo Nordisk, the Danish-headquartered manufacturer, informed the FDA on April 3 that counterfeit 1-milligram injections of semaglutide were being distributed outside its authorized supply chain. The FDA and Novo Nordisk are testing the fake products to identify whether they're safe. Patients are asked to obtain Ozempic with a valid prescription through state-licensed pharmacies and check the product for any signs of counterfeiting. People in possession of the fake product are urged to call Novo Nordisk customer care at 800-727-6500 Monday through Friday from 8:30 a.m. to 6 p.m. EDT and report it to the FDA's criminal activity division's website. Side effects can be reported to FDA's MedWatch Safety Information and Adverse Event Reporting Program (800-FDA-1088 or www.fda.gov/medwatch) as well as to Novo Nordisk, at 800-727-6500. https://www.upi.com/Health_News/2025/04/14/FDA-fake-Ozempic-drugs-Novo-Nordisk/6841744666854/ XX Can a digital lifestyle modification program reduce diabetes risk? A new study shows that the lifestyle intervention significantly reduced 10-year diabetes risk among prediabetics by nearly 46% and increased the diabetes remission rate, highlighting the importance of lifestyle changes. However, the study was not a randomized trial, and participation in the lifestyle intervention was voluntary, which may introduce selection bias. The study evaluated 133,764 adults, categorizing them as diabetic (7.5%), prediabetic (36.2%), and healthy (56.3%), based on fasting glucose and HbA1c levels. XX Chrissy Teigan is speaking out about her son’s type 1 diagnosis – teaming up with Sanofi to encourage people to screen early for Type 1 diabetes. Teigen got a crash course in the risks of undiagnosed Type 1 diabetes when her 6-year-old son, Miles, was hospitalized with complications of the autoimmune disease last year. The family knew nothing about Type 1 diabetes when Miles was diagnosed during an unexpected medical emergency, Teigen said in a Tuesday announcement. “We were confused and scared when Miles was first diagnosed,” she said in a statement. “There is no doubt in my mind that knowing in advance would have made a positive impact for Miles, me, and our entire family. I want everyone to hear me when I say: stay proactive and talk to your doctor about getting yourself or your loved ones screened for type 1 diabetes today!” Teigen shared her family’s story in a two-minute video on ScreenForType1.com, a Sanofi website that discusses how to get screened for the condition. Miles’ diagnosis made Teigen feel like she “went from a mom to a doctor overnight,” she said. That experience is why Teigen said she is “begging you: Do this one thing, and screen yourself and your family for Type 1 diabetes.” XX Dr. Richard Bernstein – best known for his advocacy around low carb diets for people with diabetes – died this week at the age of 90. Born in 1934 in Brooklyn, New York, he was diagnosed with type 1 at age 12. In the 1970s he adapted a blood glucose monitor for home use and helped pioneer home glucose monitoring. He published multiple books on Diabetes including the #1 selling Diabetes book on Amazon.Com “Dr. Bernstein’s Diabetes Solution: A Complete Guide to Achieving Normal Blood Sugars” and “Diabetes Type II: Living a Long, Healthy Life Through Blood Sugar Normalization”. He practiced and saw patients right up until his death.
/episode/index/show/diabetesconnections/id/36205185